หมวดหมู่: ACN Newswire

SINGAPORE, Mar 27, 2026 - (ACN Newswire via SeaPRwire.com) - Choosing where to place your savings in Singapore is an important financial decision that requires careful consideration. With many banks offering different types of accounts, it is easy to get confused. However, picking the right one is the first step to reaching your financial goals, whether you are saving for a dream wedding, a new home, or a retirement fund.The good news is that you no longer need to spend a whole afternoon waiting at a bank branch. You can now open a bank account online in just a few minutes using your phone or computer. Here is a simple guide to help you choose the best account for your needs in 2026.Identify Your Financial HabitsBefore focusing on interest rates, consider how you manage your money on a daily basis. Savings accounts in Singapore usually fall into two categories:The Active Saver: These accounts give you high interest rates, but you have to make a few mandatory transactions each month. Usually, you need to credit your salary and spend a set amount on your credit card.The Passive Saver: These accounts help you earn bonus interest just for keeping your money in the account and letting it grow. You do not need to worry about credit card spending or paying bills.Compare Interest RatesBefore opening a bank account online, make sure you compare the interest rates. Many basic accounts offer low interest rates. To make your money grow, you should look for bonus interest.For example, a high-interest account can offer between 2% and 5% depending on the rules you follow. If you have SGD 50,000, the difference between a basic account and a high-interest one could be hundreds of dollars in extra cash every year. Always check the effective interest rate, which tells you the real amount you will earn after all the levels are counted.Look for Welcome PromotionsBanks in Singapore are always competing for your business. When you open a bank account online, you can often grab a welcome gift, such as cash credits or rewards. These promotions are a great way to get a head start on your savings. Just make sure to check the dates, as many of these flash deals only last for a few months.Check the Fees and MinimumsEven a great account can lose you money if you are not careful about fees. Before you sign up, check for these three things:Minimum balance: Most accounts require maintaining a certain amount of money in the account at all times. If the balance drops below this limit, the bank may charge you a monthly fee.Initial deposit: Some accounts require at least SGD 1,000 to get started.ATM access: Make sure the bank has plenty of ATMs near your home or office so you do not get charged for using the machine of another bank.Open an Account OnlineOnce you have picked the right account, the final step is to fill out your application. In Singapore, you can use Singpass MyInfo to fill out your application automatically.When you open a bank account online, your details, such as your NRIC, address, and income, are pulled directly from the government database, thus reducing paperwork. Most accounts are approved almost instantly, and you can start using your new digital card right away.Final ThoughtsChoosing a savings account is not just about finding the highest interest rate. It is about finding the one that fits how you live. If you are a busy professional who already uses a credit card, an active account is perfect. If you just want to set your money aside and forget it, a passive account is better.By taking 10 minutes to compare your options today, you can ensure that every dollar you earn works as hard as you do.Disclaimer: This article is for general information only and does not have any regard to the specific investment objectives, financial situation and particular needs of any specific person. The views expressed in this article are solely those of the author. This article shall not be regarded as an offer, recommendation, solicitation or advice. You may wish to consult your own professional advisers about this article, in particular, a financial professional before making financial decisions. Any past events, trends and/or performance referred to in this article may not necessarily be indicative of future events, trends or performance. This article is based on certain assumptions and reflects prevailing conditions as at the time of publication, which are subject to change at any time without notice. The author and publisher of this article as well as any other parties associated with this article make no representation or warranty of any kind, whether express, implied or statutory, in respect of this article and accept no liability or responsibility for the completeness or accuracy of this article or any error, inaccuracy or omission relating to this article and/or any consequence, injury, loss or damage howsoever suffered by any person relating to this article, in particular, arising from any reliance by any person on this article. Publishers or platforms may be compensated for access to third party websites.Contact Information:Name: Sonakshi MurzeEmail: Sonakshi.murze@iquanti.comJob Title: ManagerSOURCE: iQuanti Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

อ่านเพิ่มเติม

- Annual sales of HuaTangNing exceeded 4 million packs, a year-on-year increase of 91%, with revenues reaching RMB 492.9 million, a year-on-year increase of 93%, marking outstanding results from the Company’s fully independent commercialization operation.- Delivered record financial performance, with profit before tax reaching RMB 1,106.4 million; maintained a robust bank balance and cash position of RMB 1,092.3 million at year-end, laying a solid foundation for sustainable operations and growth.- Gross margins rose to 56.9%, and selling expenses as a percentage of revenue were optimized to 33.6% from 59.9%, significantly enhancing profitability.- HuaTangNing  renewed its listing in the new National Reimbursement Drug List (NRDL) at the same price in 2025 for the calendar years 2026 and 2027, reaffirming its clinical and innovative value.- With the approval of PTE, market exclusivity in China granted another 5 years to April 2034, further strengthening commercial certainty.- Dorzagliatin was approved for commercialization in Hong Kong as HYHOMSIS®, accelerating its global expansion toward South-East Asia.- Multiple real-world evidence published to demonstrate therapeutic advantage of dorzagliatin.- Continuous expansion of therapeutic potential of glucose homeostasis and initiation of new first-in-disease indications study covering diabetes prevention, rare diseases, mild cognition impairment and frailty.SHANGHAI, Mar 27, 2026 - (ACN Newswire via SeaPRwire.com) – Hua Medicine ("the Company", Hong Kong Stock Exchange Stock Code: 2552) announces the audited consolidated results of the Company and its subsidiaries for the year ended December 31, 2025 (the “Reporting Period”). During the Reporting Period, the commercialization of HuaTangNing (dorzagliatin tablets), the Company’s core product – the global first-in-class innovative anti-diabetes medicine, glucokinase activator (GKA) – advanced comprehensively across all fronts, the Company’s independent commercialization team was efficiently and seamlessly established in its first year of operations, the Company’s R&D pipeline continued to be enriched, and the Company’s financial performance achieved a historic breakthrough, successfully entering a new stage of profitability, injecting strong momentum into the innovative development of the global diabetes treatment field.Dr. Li CHEN, Founder and CEO of Hua Medicine, stated: “2025 is a remarkable year in the commercialization operation of Hua Medicine. The Company has successfully advanced from R&D to commercialization driven organization and achieved the fully independent capacity in commercialization of global first in class novel glucose homeostasis regulator HuaTangNing. With strong market execution and product competitiveness, we have achieved nearly triple-digit growth in sales volume and revenue over 2024 when the commercialization was farmed out to sales and marketing partners. At the same time, the Company has made key progress in global market expansion through registration of drozagliatin in Hong Kong and position it toward 700 M population in south-east Asia. We continue to expand the clinical application of glucose homeostasis regulation technology and engage in new indications such as early-stage Alzheimer’s disease and Frailty. The first-in-disease efforts in GCK-MODY and Frailty set the new innovation course of Hua Medicine in the next 5 years.” Business Highlights and Operational Progress- Fully Powered Commercialization, Historic Breakthrough in ProfitabilityOn January 1, 2025, the Company assumed full responsibility for the commercialization of HuaTangNing, allowing the company to consolidate both operational and strategic control over market execution in China. The Company successfully built a professional sales team covering 10 sales regions around the country, focusing on marketing, medical affairs and commercial operation. Through an AI-empowered digital commercialization platform, operational efficiency and sales productivity were greatly enhanced, injecting new vitality into the Company’s commercial development.Reimbursement coverage under the NRDL has significantly increased accessibility, especially in Tier 2 and Tier 3 hospitals, and played a critical role in accelerating patient adoption. Since its launch in October 2022, HuaTangNing has been prescribed to over 500,000 patients through 3,000+ hospitals, community centers, pharmacies and online channels.Sales performance exceeded expectations, with 4.011 million packs of HuaTangNing sold during the reporting period, representing a 91% increase over the fiscal year 2024. This growth was achieved at the same price for both periods, underscoring strong demand and successful execution of Hua’s commercial strategy.In terms of profitability, the Company’s gross profit reached approximately RMB280.4 million, a year-on-year increase of 125%. Thanks to expanded production scale and optimized manufacturing processes, the Company’s gross margin improved to 56.9%,  increasing by 8.2 percentage points as compared to 48.7% for the year of 2024. Selling expenses increased only by RMB12.3 million to RMB165.5 million, reflecting a significant positive trend towards profitability when our selling expenses in the 2025 fiscal year represents only 33.6% of revenue, whereas in the 2024 fiscal year, our selling expenses represented approximately 59.9% of revenue. In fiscal year 2025, our commercialization efforts achieved profits of approximately RMB114.9 million (as defined by gross profits less selling expenses). Although we expect to continue to increase personnel to our commercialization team, we expect this profitability trend in our commercial operations in mainland China to continue.Following the termination of the collaboration with Bayer at the end of 2024, dorzagliatin achieved a record-high sales volume. Profit before tax increased to RMB1,106.4 million for the fiscal year 2025. We ended fiscal year 2025 with a cash position of approximately RMB1,092.3 million.- Accelerated Global Layout, Strengthened Core Rights and InterestsThe Company took a key step in global expansion. On February 27, 2026, dorzagliatin (trade name: MYHOMSIS®, was successfully approved for marketing by the Hong Kong regulatory authority. The Company plans to officially launch the product in the Hong Kong market by the middle of 2026 and further expand to Asian regions. In addition, the Company submitted a new drug registration application in Macau in 2025.The Company also made new progress in intellectual property protection. In February 2026, the patent term extension (PTE) application for dorzagliatin was formally approved by the China National Intellectual Property Administration, thereby the core patent protection period of dorzagliatin extended to April 2034 and an additional 5-year market exclusivity obtained, which provides a strong guarantee for the product’s long-term market competition.In 2025, dorzagliatin was recognized as national innovation and an effective therapy for chronic diseases by the regulatory authorities in China. Accordingly, the same NRDL price was offered for the calendar years 2026 and 2027. Reimbursement coverage under the NRDL has significantly increased accessibility, especially in Tier 2 and Tier 3 hospitals, and played a critical role in accelerating patient adoption. The Company will continue to safeguard the product’s market competitiveness and patient accessibility and accelerate the popularization of the drug among patients.- Advancement of Real-World Studies, Continuous Validation of Clinical ValueReal-world evidence (RWE) studies continue to corroborate the key role of dorzagliatin in improving glucose-dependent pancreatic islet secretion function, and demonstrate its efficacy in diabetes prevention, remission, and delaying or preventing diabetes complications.The RWE study sponsored by Hua Medicine HMM0701 with 380 T2D patients was fully enrolled in 2025. The interim analysis, as reported at the 2025 American Diabetes Association (ADA), showed that 86% of such patients were taking two or more antidiabetic drugs and 41% of such patients were using insulin. After a 6-month treatment, a significant improvement of glycemic control was observed with HbA1c reduction from 8.1% to 7.3% with the mean time-in-range (TIR) levels increasing to over 70%. Thus far, the studies have demonstrated that when dorzagliatin is administered in combination with other antidiabetic drugs, such patients have experienced significantly improved post-meal glucose levels and improved β-cell function.Separately, a mechanistic study with dorzagliatin (employing double-tracer measurement) was conducted in the United States to provide scientific evidence of hepatic glycogen formation in T2D patients with an average of 17 years of diagnosed diabetes. In this study, patients were treated with dorzagliatin twice daily for 6 weeks. The results showed that dorzagliatin increased direct glucose flux to hepatic glycogen implying the improvement of restoration of hepatic Glucokinase (GK) function. Together with the clinical research data that dorzagliatin improves early phase insulin release and GLP-1 secretion, recovery of hepatic glycogen synthesis in T2D patients offers an important path in controlling post-meal glucose excursion and provides a unique opportunity in controlling diabetes complications, such as diabetes kidney diseases and mild cognition impairment.The RWE sponsored by Hua Medicine (HMM0601) has completed clinical trials with over 2,000 subjects, with average diabetes duration of 7.9 years and above 30% having disease duration more than 10 years. The initial results suggest that dorzagliatin is safe and well tolerated in Chinese T2DM patients. There were no new adverse effects observed in the study and the incident rate remains as low as what was observed in Phase III clinical trials. Patient adherence was generally high, with a mean adherence rate of approximately 95%. In this study, 80% of the participants have used one or more oral anti-diabetes medicine, and 20% used insulin. Dorzagliatin demonstrated good efficacy and safety not only in the overall population but also in elderly, obese, and hyperglycemic patient populations, whether used as monotherapy or in combination with metformin, SGLT2 inhibitors, insulin, and other medications. The topline results will be reported at the 2026 American Diabetes Association.- Deepened Clinical R&D, Continuous Expansion of New IndicationsNew Indication for Dorzagliatin – MODY-2 Patients.Medical experts in mainland China and Hong Kong have conducted independent clinical and preclinical studies of dorzagliatin for MODY-2 treatment. MODY-2, also called GCK-MODY, is a monogenic disease in which patients have a genetic defect of glucokinase gene (GCK) which results in elevated blood glucose and significant reduction of the second phase insulin secretion. The population of GCK-MODY patients is approximately 1.7 million in China. These patients are diagnosed with diabetes at a young age and represent an unmet medical need given that currently available medications are not effective. In clinical studies with MODY-2 patients, China investigators have reported that dorzagliatin is effective in reducing blood glucose levels to normal levels in MODY-2 patients who previously failed to manage their elevated blood glucose levels when treated with metformin, TZD, DPP-IV inhibitors, and SGLT-2 inhibitors. Additional results demonstrated that a single dose of dorzagliatin improved overall glucose sensitivity and second phase insulin secretion significantly in GCK-MODY patients, suggesting a unique mechanism of action of dorzagliatin to regulate GLP-1 secretion. Based on such results, Hua Medicine has communicated and reached a consensus with the CDE at NMPA to file the IND submission of dorzagliatin for MODY-2 patients in 2026.Dorzagliatin for Diabetes Prevention.Prevention of diabetes is an important focus at Hua Medicine. There are approximately 1.12 billion people living with prediabetes worldwide. We have initiated SENSITIZE 3 clinical study in Hong Kong in pre-diabetic (IGT) subjects and in early diabetes patients. These studies represent first-in-disease studies. In this double-blinded placebo-controlled study, we will evaluate the blood glucose management and pancreatic function under IVGTT and OGTT conditions to better define the clinical treatment baseline and endpoints. We expect to complete this study in 2026 and explore the opportunity to file IND applications of dorzagliatin for diabetes prevention in China and Asian Pacific regions thereafter. Dorzagliatin for Neurodegenerative Diseases.MCI shows approximately 15.5% prevalence among elderly people in China and approximately 22% in the US, and is common in T2D patients with a 45% incidence rate. The development of dorzagliatin for neurodegenerative disease is a new focus in our drug discovery efforts. Through the Genome-Wide Association Study (GWAS) and Mendelian Randomization (MR) study, we have realized the important role of GCK gene activation in the prevention of memory loss and cognitive impairment in humans. It has also come to our attention that post-meal glucose excursion is closely related to Alzheimer disease and dementia. The bio-energy balance in the brain is largely dependent on the glucose homeostasis control in the peripheral organ and the neural network communication in the central and peripheral system via spatial temporal management. Impaired glucose homeostasis and diabetes conditions result in a reduction of glucose transporter expression and insulin receptor expression in the brain, which can be prevented by low dose dorzagliatin. We have realized the potential of dorzagliatin in the treatment of mild cognitive impairment (MCI) and will initiate these first-in-disease clinical studies in the future.Dorzagliatin for Frailty.Frailty is an age-related geriatric syndrome characterized by reduced tolerance to internal and external stressors. Approximately 17% of Americans and 11% of Asians over the age of 50 suffer from frailty, while pre-frailty affects roughly 50% and 47% of these populations, respectively. It is not a single-organ disease, but the consequence of dysregulated multisystem homeostasis. Genetic evidence supports the causal effects of glucokinase (GK) activation on lowering frailty risk. We plan to initiate clinical studies in the future to advance dorzagliatin’s application in frailty.Development of combination therapy for diabetes and complications.Dorzagliatin rescues pancreatic function in glucose insulin secretion and GLP-1 secretion, as evidenced by clinical and basic research results. It also improves hepatic insulin sensitivity and reduces hepatic insulin resistance through recovery of hepatic glycogen synthesis in T2D patients. The combination of dorzagliatin with DPP-IV inhibitors, SGLT-2 inhibitors, and GLP-1 agonists have demonstrated effective regulation of lipid metabolism. Studies in combination with anticancer PI3K inhibitors have also offered unique benefits for glucose homeostasis management.- Diversified Product Pipeline, Innovative Layout for Future GrowthHua Medicine continues to enrich its pipeline layout based on core products. The Company has accelerated the R&D of a fixed-dose combination (FDC) of dorzagliatin and metformin as a twice-daily therapy for Type 2 diabetes patients with inadequate glycemic control on metformin alone, to further improve patient medication compliance. The product is supported by the strong results of the loose-dose combination in both Phase III clinical trials and real-world use. The Company has submitted an IND application to NMPA, and the GMP commercial manufacturing process has been successfully carried out, preparing for the pivotal bioequivalence study for NDA filing in 2027. Clinical studies have shown that the combination of dorzagliatin and metformin can better control blood glucose, reduce postprandial blood glucose and improve fasting blood glucose, providing new clinical value for optimizing blood glucose homeostasis endpoints.We have advanced our 2nd generation GKA as a once daily therapy for patients with obesity, leveraging dorzagliatin effects in improved glucose-stimulated GLP-1 secretion in the pancreas and in the intestine. The MAD study of the 2nd generation GKA was initiated in the United States with first-patient-in in December 2025, and we expect to report topline data by the middle of 2026.Meanwhile, the Company is also exploring combination therapy regimens of dorzagliatin with GLP-1 receptor agonists, SGLT-2 inhibitors and other drugs. In a recently published clinical trial in China, researchers reported the superior benefits of our dorzagliatin in combination with semaglutide as compared to semaglutide alone in a 12-week study. The combination group showed superior results across several key measures, including glycemic control, bodyweight related indicators and β-cell function.Financial Summary- Revenue generated by the Company was approximately RMB 492.9 million from the sale of approximately 4.011 million packs of HuaTangNing, increases of approximately 93% and 91% respectively, as compared with the year ended December 31, 2024.- Gross profit generated by the Company for the year ended December 31, 2025, was approximately RMB280.4 million, representing an increase of approximately 125%, as compared with the year ended December 31, 2024, and gross margins rose to 56.9%.- Profit before tax increased by approximately 542% to approximately RMB1,106.4 million for the year ended December 31, 2025, as compared with the year ended December 31, 2024.- Bank balances and cash position was approximately RMB1,092.3 million as of December 31, 2025.- Expenditures incurred by the Company for the year ended December 31, 2025, were approximately RMB433.4 million.Forward-Looking StatementsThis document contains statements regarding Hua Medicine's and its products' future expectations, plans and prospects. Such forward-looking statements relate only to events or information as of the date on which the statements are made in this document and are subject to change in light of future developments. Except as required by law, the Company shall not be obligated to update or publicly revise any forward-looking statements or unforeseen events after the date of such statements, whether as a result of new information, future events or other circumstances. Please read this document carefully and understand that actual future performance or results of the Company may differ materially from expectations due to various risks, uncertainties or other statutory requirements.About Hua MedicineHua Medicine (The “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment. In February 2026, dorzagliatin (Trade name: MYHOMSIS®,) was approved for marketing by the Pharmaceutical Services of the Department of Health of the Government of the Hong Kong Special Administrative Region of China.For more informationHua MedicineWebsite: www.huamedicine.comInvestorsEmail: ir@huamedicine.comMediaEmail: pr@huamedicine.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

อ่านเพิ่มเติม

HONG KONG, Mar 27, 2026 - (ACN Newswire via SeaPRwire.com) – 26 March, Unisound (09678.HK) announced its audited annual results for the year ended December 31, 2025. As the Company's first annual results announcement since listing, it underscores strong growth momentum and continued improvement in its financial profile.Revenue Mix Continues to Improve, with Faster Growth in H2For the full year of 2025, Unisound achieved total revenue of $175 million, representing a year-on-year (YoY) increase of 29%. Revenue in the second half of the year increased by 33% YoY to $117 million.It is worth noting that the Company's large language model (LLM) business generated a full-year revenue of $88.43 million, surging by over 10 times YoY. In particular, this business contributed approximately $72.49 million in H2 revenue, five times the level recorded in H1, demonstrating a compelling capacity for large-scale commercial application.Losses Narrowed Significantly, Making the Path to Profitability Increasingly ClearAlongside the rapid revenue growth, the Company's losses improved markedly. In the second half of 2025, the Company's net loss narrowed by 84% YoY, and its adjusted loss narrowed by 92% YoY, approaching break-even. This reflects the Company's ongoing improvements in cost control and operational efficiency.Simultaneously, some of the Company's operating metrics saw marked improvement. The adjusted expense ratio declined significantly by 10 percentage points YoY, while selling expenses decreased rather than increased and accounted for only 5.4%, highlighting a clear improvement in cost-to-efficiency ratio. In 2025, revenue per employee reached $365,300, up 25% YoY from $292,900 in 2024. Employee productivity continued to lead the industry, clearly underscoring the Company's core strengths in technology-driven, lean operations.Dual-Engine Strategy Gains Traction, with AI in Healthcare and AI in Daily Life Advancing in TandemIn 2025, driven by both technological breakthroughs and policy tailwinds, global demand for AI continued to rise. Unisound adhered to its "Strong Foundation Model + Deep Application" strategy, continued to strengthen its multimodal technology foundation, and drove the continuous elevation of the global influence of its proprietary large model matrix in fields such as healthcare, speech, and OCR.On the commercialization front, the Company leveraged its AI-native organization to accelerate business execution, and its dual-engine strategy in AI in Healthcare and AI in Daily Life delivered notable results. During the reporting period:The AI in Daily Life business achieved revenue of $140 million, a YoY increase of 30.8%. Among this, the Transportation segment recorded nearly 40% YoY growth. At present, AI agent applications based on the Shanhai large model have been deployed in more than 10 cities, including Qingdao, Ningbo, Shenzhen and Nanning. In addition, cumulative AI chip shipments exceeded 110 million units, further validating the Company's scale capabilities in endpoint AI products.The AI in Healthcare business achieved revenue of $35.38 million, a YoY increase of 22.3%, with average revenue per customer growing by 53.2% YoY. In 2025, over 70% of the hospitals the Company collaborated with were tertiary hospitals, and more than one-third of customers had maintained continuous cooperation for over three years. The medical-record entry and generation products powered by the medical large model delivered a 10-fold YoY increase in full-annual medical record generation at a single campus of a leading Class III hospital. The commercial insurance AI agent platform recorded a 37-fold YoY increase in case processing volume. In deep cooperation with a leading insurance group, the expense control rate was effectively raised to approximately 20%, delivering more than $145 million in incremental cost management compared with traditional review methods, comprehensively empowering insurance institutions to refine their medical risk management operations.Continued R&D Investment Strengthens the Technology MoatTo consolidate its industry-leading position, the Company continued to invest heavily in R&D in 2025. Full-year R&D expenses exceeded $55.09 million, accounting for 75% of the Company's adjusted operating expenses, while R&D personnel accounted for 69% of the total workforce. This sustained investment drove breakthroughs across multiple technology areas. For example, in the MedBench 4.0 evaluation, the Company ranked first place in three technical paradigms: "Medical AI Agent," "Medical Large Language Model," and "Medical Multimodal Large Model," earning a "Triple Crown."Outlook: Deepening the Technological Foundation and Expanding Application BoundariesLooking ahead, Unisound will continue to deepen its "Strong Foundation Model + Deep Application" strategy. On the technological front, the Company will continue to increase strategic investment in foundational large models and strive to maintain a world-class level. On the application front, it will use the large-scale expansion of MaaS (Model-as-a-Service) and AI agents as its core growth engine, driving exponential growth in its AI in Daily Life and AI in Healthcare businesses. Meanwhile, the Company is actively exploring the establishment of a recurring revenue system through models such as API calls and Token-based billing, and regards opportunities in consumer-facing (C-end) products as a second growth curve to further expand its commercialization boundaries.Between Q2 and Q3 2026, Unisound will launch a native AI agent large model for programming and office applications, which is expected to double both intelligence density and token production efficiency. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

อ่านเพิ่มเติม

Financial HighlightsRMB 100 millionFor the 12 months ended 31 DecemberChange (%)20252024Revenue1566.111,776.64-11.85% Profit28.4265.53-56.64% Profit before Tax28.1665.95-57.30% Gross Profit194.95222.47-12.37% Gross Profit Margin12.45%12.52%-0.07pct Net Profit13.3741.95-68.12% Net Profit Attributable to Shareholders and Other Equity Holders2.2129.72-92.57% Net cash flows from operating activities 185.1492.6499.86% Dividend per share (RMB/share, tax inclusive)RMB 0.179RMB 0.176N/A Total dividend payout9.399.45-0.60%  Performance Highlights1. Solid operating core segments with resilient high-quality development: In 2025, the Group achieved revenue of RMB 156.611 billion, net profit of RMB 1.337 billion, and maintained a gross profit margin of 12.45%, with a balanced domestic and overseas revenue structure.2. Dual improvement in cash flow and financial quality, with significantly enhanced risk resilience: Net cash flows from operating activities increased substantially by 99.86% to RMB 18.514 billion, while the cash and cash equivalents as of the end of the Year reached RMB 24.3 billion; the scale of interest-bearing debt decreased by RMB 4.7 billion year-on-year (“YoY”) to RMB 34.4 billion, and net interest expenses decreased by approximately RMB 730 million YoY, with the financial structure continuing to be optimized.3. Cash dividends and share buybacks implemented in parallel to reward investors: The Group proposes a cash dividend of RMB 0.179 per share (tax inclusive) for 2025. Together with multiple rounds of H-share and A-share buyback plans launched during the Year, the total proposed dividend and completed buybacks for 2025 amounted to RMB 1.852 billion.4. Significant improvement in profitability of energy-related businesses, becoming a key growth driver of the Group: Net profit of the offshore engineering segment and the financial and asset management segment (primarily drilling platform leasing) increased by approximately RMB 1.212 billion in total, while the energy, chemical and liquid food equipment segment increased by RMB 308 million. Among them, the gross profit margin of the offshore engineering segment increased significantly by 5.72 percentage points to 14.83%. Orders on hand for offshore engineering and energy, chemical and liquid food equipment reached US$5.09 billion and RMB 29.75 billion, respectively, with certain shipyards’ production schedules extending to 2030.5. Logistics-related businesses continued to serve as the Group’s “ballast stone”: During the Year, businesses such as container manufacturing and road transportation vehicles were affected by exchange rate fluctuations and cyclical changes, resulting in pressure on gross profit margins and profitability. However, the core segments remained solid, and the Group’s competitive advantages in the industry continued to be consolidated. Core products such as standard dry containers, reefer containers, tank containers and semi-trailers have maintained the world’s No.1 position for many consecutive years.6. Breakthroughs in both technology and orders in key businesses, with competitiveness highly recognised: In the high-end offshore engineering equipment sector, CIMC Raffles successfully developed the most complex products in the offshore industry, including FPSO/FLNG, becoming the only enterprise in China with dual-project EPCI general contracting capabilities; in the modular data center sector, the Group providing technical and manufacturing delivery services of prefabrication data center to industry customers exceeding 300MW, leading new transformation in computing power infrastructure.HONG KONG, Mar 26, 2026 - (ACN Newswire via SeaPRwire.com) – China International Marine Containers (Group) Co., Ltd. (“CIMC Group” or the “Group”, stock code: 000039.SZ/02039.HK) is pleased to announce the audited annual results for the 12 months ended 31 December 2025 (the “Year”).The Group’s management stated, “In 2025, profound global changes unseen in a century accelerated, and the global economy demonstrated resilience amid volatility. Positioned in an era of both opportunities and challenges, the Group closely adhered to the strategic theme of “accelerating the construction of new growth drivers and focusing on promoting high-quality development”. While stabilising its operating fundamentals, the Group further deepened its forward-looking strategic layout in the energy business and achieved fruitful results. For the year of 2025, the Group recorded revenue of RMB 156.61 billion and net profit of RMB 1.34 billion. Cash flows from operating activities increased significantly by 99.9% to RMB 18.51 billion, with the asset structure continuously optimized and risk resilience further enhanced.”In particular, to sincerely reward investors, CIMC Group proposes to distribute a cash dividend of RMB 0.179 per share (tax inclusive) to all shareholders for 2025, amounting to a total proposed cash dividend of RMB 939 million (tax inclusive). Meanwhile, the Group implemented share buybacks totalling RMB 913 million during 2025, bringing the combined total to RMB 1.852 billion.Segments Results (RMB 100 million)2025 Business indicatorsRevenueAs % of the total revenueGross profitAs % of the gross profitGross profit marginNet profitContainer manufacturing430.0927.46%57.5529.52%13.38%18.82Road transportationvehicles201.7812.88%32.0616.45%15.89%9.27Energy, chemical, and liquid food equipment271.9217.36%40.2420.64%14.80%10.40Offshore engineering179.3811.45%26.6013.65%14.83%10.57Logistics services267.9317.11%16.708.57%6.23%3.64Airport facilities and logistics equipment/fire safety and rescue equipment76.194.86%15.147.76%19.87%2.64Total of major segments1427.2991.12%188.2996.59%13.19%55.34Core Business Performance1. In logistics field:In the container manufacturing business, during the Year, despite negative supply chain factors such as U.S. tariff policies and geopolitical conflicts, global merchandise trade demonstrated strong resilience. Intra-regional trade, Asia-Europe routes and emerging market routes became the main drivers of incremental growth. Meanwhile, factors such as detours around the Red Sea, port congestion, environmental requirements in shipping and increasing complexity of trade routes reduced transportation efficiency, structurally boosting underlying demand and pushing the global container fleet into a new structural phase. As a result, overall demand for new containers in 2025 remained at a relatively high level, exceeding the average of the past decade. During the Year, the production and sales volume of the Group’s container manufacturing business declined YoY, in line with overall industry expectations, but the Group maintained its global No.1 position. Accumulated sales volume of dry cargo containers reached 2,224,900 TEUs (2024: 3,433,600 TEUs), representing a YoY decrease of 35.2%. Accumulated sales volume of reefer containers reached 208,200 TEUs (same period last year: 138,600 TEUs), representing a YoY increase of 50.2%. During the Year, the container manufacturing segment recorded revenue of RMB 43.009 billion, net profit of RMB 1.882 billion, and a slight decline in gross profit margin to 13.38%.In the logistics services business, during the Year, the segment recorded revenue of RMB 26.793 billion, representing a YoY decrease of 14.64%, and net profit of RMB 364 million, representing a YoY decrease of 16.65%, in line with industry trends. CIMC Wetrans actively adjusted its business structure and integrated resources. During the Year, self-sourced cargo volume increased by 6% YoY, while second-hand container trading and warehousing distribution in port logistics reached record highs. The industry logistics business focused on key sectors such as new energy, automotive and engineering projects to consolidate its niche advantages. In 2025, CIMC Wetrans ranked among the top five for three consecutive years in the “Comprehensive List of Freight Forwarding and Logistics Enterprises” published by the China International Logistics and Freight Forwarding Association.In the road transport vehicles business, during the Year, CIMC Vehicles recorded revenue of RMB 20.178 billion, representing a YoY decrease of 3.91%, and net profit of RMB 927 million, representing a YoY decrease of 14.29%. In the domestic market, the “Star-Chained Plan” reshaped the organisational and operational model, with revenue from the China semi-trailer business increasing by 14.65% YoY and gross profit margin increasing by 3.3%YoY. In overseas markets, the Global South markets maintained high-quality growth, with revenue reaching RMB 3.09 billion during the Reporting Period, representing a YoY increase of 17.7%, sales volume increasing by 29.1% YoY, and gross profit margin increasing by 1.3 percentage points YoY.The DTB business achieved steady growth in both sales volume and revenue, with a total of 28,570 units of mounted equipment products delivered, generating total revenue of RMB 3.184 billion, representing a YoY increase of 4.97%, with further improvement in market share of core products. Meanwhile, the Group continued to actively expand R&D and sales of new energy products, comprehensively building the EV-RT ecosystem and advancing the strategic development of pure electric tractors and trailers.In the airport facilities and logistics equipment/fire safety and rescue equipment, benefiting from the release and delivery of high-quality orders, the segment recorded revenue of RMB 7.619 billion during the Year, representing a YoY increase of 5.92%, and net profit of RMB 264 million. Airport equipment successfully delivered smart boarding bridges projects for Xi’an Xianyang International Airport, Antalya Airport in Türkiye and Lanzhou Airport, and secured major projects including Phase II of Nanning Airport and corridor projects at Hangzhou Airport T2 and T4 with its independently-developed innovative prefabricated fixed bridge solutions. Logistics equipment delivered automated three-dimensional warehouse systems for supporting the petrochemical and refining integration project in China. The fire safety and rescue equipment business advanced the overseas expansion of domestically manufactured products while focusing on frontier areas such as smart fire safety and unmanned fire trucks.2. In the Energy FieldIn the energy, chemical, and liquid food equipment business, the segment recorded revenue of RMB 27.192 billion, representing a YoY increase of 6.31%, and net profit increased significantly by 42.15% to RMB 1.040 billion. Among which, CIMC Enric recorded revenue of RMB 26.326 billion, representing a y YoY increase of 6.3%.Specifically, the clean energy segment advanced both offshore and onshore businesses, maintaining leading market share in key equipment such as high-pressure and cryogenic equipment, while capturing growth opportunities in natural gas applications in water and land transportation and power generation, and actively expanding into emerging markets for special industrial gas equipment in high-tech industries. In 2025, the segment secured new orders of RMB 22.229 billion, a record high. Among these, orders on hand for offshore clean energy-related business exceeded RMB 19 billion as of the end of 2025, with shipbuilding schedules extending to 2028. During the Year, the second coke oven gas comprehensive utilisation project — Linggang Phase I project — was successfully put into operation, and China’s first domestic mass-production bio-methanol (green methanol) project of CIMC Enric was completed and commenced operation. The chemical and environmental segment maintained its leading market share, while the medical equipment components and after-sales service businesses achieved steady growth. As of the end of 2025, orders on hand increased by 36.27% YoY to RMB 1.276 billion, providing strong support for future development. The liquid food segment maintained stable profitability, with gross profit margin increasing to 21.7% YoY.In the offshore engineering business, the Group’s core operating entity, CIMC Raffles, successfully achieved a strategic transformation from “manufacturing-led” to integrated “design + construction + integration” services, maintaining a leading position in the domestic market and emerging as an important new force in the international offshore engineering market. During the Reporting Period, the segment recorded revenue of RMB 17.938 billion, representing a YoY increase of 8.35%, and net profit of RMB 1.057 billion, becoming the Group’s second-largest profit contributor. Benefiting from the recovery of the global offshore engineering market, demand for high-end oil and gas equipment represented by FPSO/FLNG remained strong, while the industry accelerated its transition toward green and intelligent development, driving steady growth in new energy equipment orders. During the year, the Group secured new contract orders of US$1.20 billion, including 12+8 container feeder vessels, 2 offshore engineering special vessels and other module orders. As of the end of 2025, the accumulated value of orders on hand reached US$5.09 billion, with orders for oil & gas and special vessel accounting for approximately 70% and 30%, respectively. The Longkou base has scheduled production through to 2030.In the offshore engineering asset operation and management business, the Group continued to leverage its existing project experience and business capabilities, enhancing asset utilisation through its strong offshore platform operation and management capabilities. During the Reporting Period, the sixth-generation semi-submersible drilling platform “Deepsea Yantai” completed lease renewal, the ultra-deepwater semi-submersible drilling platform “Blue Whale No.1” signed a new lease with an international client, and the semi-submersible lifting/life platform “Blue Gretha (formerly Huadian CIMC 01)” also secured a new lease with an international client. Other platforms actively participated in market tenders to explore opportunities for asset disposal and leasing. During the Reporting Period, the average daily lease rate of semi-submersible and jack-up drilling platforms both recorded year-on-year increases.Future Development and ProspectsThe Group’s management stated, “The year 2026 marks the beginning of the ‘15th Five-Year Plan’. Starting from a newly upgraded brand identity, the Group will closely focus on ‘consolidating foundations, driving innovation, improving quality and efficiency’, and adopt a more proactive strategic approach to foster new opportunities and open new horizons amid complex changes, striving to build a ‘“becoming a high quality and trustworthy world-class multimodal transport enterprise.”About China International Marine Containers (Group) Co., Ltd.The CIMC Group is a world-leading equipment and solution provider in the logistics and energy industries, with its industry clusters mainly covering the logistics and energy fields, continuously strengthening its leading market position. In the logistics field, the Group continues to adhere to container manufacturing as its core business, based on which it has incubated the road transportation vehicles business and the airport facilities and logistics equipment / fire safety and rescue equipment business, supplemented by the logistics services business and recycled load business, providing products and services in the professional logistics field. In the energy field, the Group is principally engaged in the energy, chemical and liquid food equipment business and the offshore engineering business. Meanwhile, the Group continues to develop emerging industries and possesses financial and asset management businesses that serve the Group itself. As a diversified multinational industrial group serving the global market, CIMC has over 300 member enterprises across Asia, North America, Europe, and Australia, with a total of four listed companies, and customers and sales networks covering more than 100 countries and regions worldwide. In 2025, the Group recorded revenue of RMB 156.6 billion, ranking 154th on the 2025 Fortune 500 China list. The Group has maintained the world’s No.1 position for many consecutive years in core products such as standard dry containers, reefer containers, tank containers and semi-trailers. For more information, please visit http://www.cimc.com/. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

อ่านเพิ่มเติม

Financial Highlights (Audited)(HKD Thousand)Year ended31 December20252024Revenue170,011271,372Gross Profit53,382104,720Profit Attributable to Owners of the Company13,68833,440Basic Earnings per Share (HK cents)0.972.37HONG KONG, Mar 26, 2026 - (ACN Newswire via SeaPRwire.com) - Dynasty Fine Wines Group Limited (“Dynasty” or “the Group”) (Stock Code: 00828), a premier grape winemaker in China, today announced its audited annual results for the year ended 31 December 2025 (“the Year”).In 2025, due to the impact of macroeconomy as well as weak demand in wine consumer market in the PRC, the Group’s sales of medium to high-end products significantly declined, resulting in a 37% year-on-year decrease in revenue to HK$170.0 million. In addition, due to the decline in sales revenue and gross margin, as well as an increase in loss allowances for trade receivables owing to extended repayment from certain distributors, the profit attributable to owners of the Company decreased by 59% year-on-year to approximately HK$13.7 million, although such decrease in profit was already partly offset by a net gain on compensatory surrender recognised during the year. Earnings per share of the Company was HK0.97 cents per Share.With strengthened marketing effort for dry white in coastal region and the launch of new white wine and sparkling wine products, sales of white wine products served as the Group’s primary revenue contributor. Sales of red and white wines products accounted for approximately 39% and 54% of the revenue respectively for the year (2024: approximately 41% and 56% respectively). The gross margin of red wine products and white wine products in 2025 were 25% and 35% respectively (2024: 36% and 41% respectively). The overall gross profit margin decreased to 31% in 2025 (2024: 39%), mainly due to change in product mix with more products with lower prices and margin in response to market dynamics and needs during the year.The Group has been actively pursuing innovation, embracing the “5+4+N” product strategy, with “N” standing for developing various customised products and continuously creating new products to meet the diverse needs of different Chinese consumer groups. During the year, the Group launched a new gift set product, i.e. Dynasty Chinese Zodiac Commemorative Dry Red Wine for the Yi Si Year of Snake, integrating with the Chinese zodiac culture and the leading rise of Chinese-style fashionable products, by presenting the zodiac culture in a youthful visual language to attract potential consumers. In addition, based on its existing high-quality products, the Group continues to introduce new products and promote product upgrades. The Group participated in the 112th China Food & Drinks Fair in March 2025, introducing new products such as Tianyang Tea-flavoured wine series, Dynasty Baifu VSOP brandy, etc., to further improve its product matrix and provide consumers with diverse consumption choices. Breaking through from the constraints of traditional wine, this tea-flavoured wine series, with its core concept of “tea and wine fusion,” has captured market attention with its unique craftsmanship. During the China Food & Drinks Fair, the Group also held wine-tasting events, where the new wines from Dynasty Ningxia Winery won industry praise for their unique flavor and exquisite craftsmanship. In the second half of the year, the Group also introduced new products “Hi” tea-flavoured wine series in response to the market need, which are very suitable for ready-to-drink scenarios among young consumers.In addition to enriching the product matrix, the Group has been closely cooperating with distributors, pressing ahead with its marketing campaign, accelerating the innovation of consumption scenarios, and enhancing and strengthening the wine cultural experience. The Group held its national tour tasting and business events, new products launch ceremonies at various exhibitions and wine fairs, as well as promotion activities for the 20th anniversary of listing in Hong Kong, during which the Group actively promoted its latest product mix that covered all product lines.During the year, two joint venture companies approved by the Group were established in February 2025, for the manufacturing and sales of yellow wine and Chenpi wine and trading of sauce-flavour baijiu products nationwide in the PRC respectively. For the yellow wine project, installation and testing of production equipment of a manufacturing plant with a tank capacity of 3,000 tonnes of yellow wine and special yellow wine – Chenpi wine in Jiangsu is expected to be completed in the second half of 2026. Upon completion of the project, the Group will be able to produce special yellow wine – Dongtai Chenpi Wine which allows the Group to effectively expand product categories, seize development opportunities in the Chinese yellow wine industry. The project expansion aims to effectively implement Dynasty’s strategic plan, further improving the industrial layout, expanding category tracks, tapping into industry potential, creating new performance growth points, and realising Dynasty Group’s transformation into a full category, full industry-chain enterprise. For the sauce-flavour baijiu segment, Dynasty sauce-flavour baijiu products, namely ‘Han’, ‘Tang’, ‘Song’ and ‘Ming’ have been newly launched in the core-market in Tianjin and Shanghai and will be further strategically promoted to other regions in 2026. The sauce-flavour baijiu products satisfy the needs of customer groups with different spending habits and contributing to the Group’s business. In the future, the continuous development and expansion of the sauce-flavour baijiu industry and the improvement of the level of customer groups will inevitably and effectively drive the increase in the sales scale of Dynasty wine and related products, thereby enhancing our industry influence and brand awareness.Regarding online sales, the e-commerce team of the Group comprehensively operates online stores itself on the traditional e-commerce platforms, such as JD.com, Tmall and Pinduoduo  for product sales, as well as comprehensive innovation on its brand, product categories, and business systems, procedures and models via interest-based e-commerce platforms, including Rednote, Kuai and TikTok. The Group continues investing resources in a timely manner for improvement of the online sales channels and optimisation of online stores interface so as to capture the change of customer consumption behaviour in the PRC. The Group jointly develops exclusive products with leading e-commerce platforms, and promote AI livestreaming models in various channels to increase brand exposure and livestreaming sales, adopts big data analysis to accurately understand consumer demand, and injects strong momentum into the continued expansion of market scale. To establish an online brand matrix, the Group selected and authorised new online distributors during the year. The Group believes that the online platforms not only serve as business-to-customer trading platforms between the Group and the consumers, but also additional marketing and promotion channels for the brand, which can enhance the overall business potential of the Group.During the year, the Group had boasted brilliant results in major wine appraisal competitions. Among the numerous awards, “Dynasty Jin. Y Brandy XO barrel-aged 12 years” has won the Silver Award, at the 2025 International Wine & Spirit Competition (“IWSC”). The competition is considered the international standard for wine and spirits quality. Dynasty Baifu VSOP Brandy, Golden Dynasty Marselan Dry Red Wine, as well as Tianyang Tea Wine series are also awarded at the “2024 Qingzhuo Awards” in respective categories by China Alcoholic Beverages Association. “Dynasty Mengyuan White wine” has also won the Grand Gold Medal at the France International Wine Awards (“FIWA”) China region, Spring 2025 for its excellent quality. In addition, “Dynasty Inherit series – Dry Red Wine” has garnered the Gold Award at the same competition. These wines stood out from other entries for their elegant aroma, smooth body and round taste, and won the awards at the competitions, showing the charm and strengths of Dynasty wines to the country and the world. Dynasty has won the Silver Medal in the Sparkling Wine/China category, the Silver Medal in the Dry Wine/China category, and the Bronze Medal in the Medium/China category for its Dynasty Tianyang Winery Jasmine Sparkling Wine, Dynasty Inherit Series – Dry Red Wine, and Dynasty Inherit Series – Semi Dry White Wine, respectively, at the 2025 Cathay Global Wine & Spirits Awards Asia (“GWSAA”) (formerly known as the Cathay Hong Kong International Wine & Spirit Competition (“HKIWSC”)). This marks the 15th consecutive year that Dynasty products have won awards at the event, demonstrating industry-wide recognition of Dynasty’s exceptional winemaking skill and quality. In addition, “Dynasty Pinyue VSOP brandy” also won the Gold Medal in the brandy category of 2025 China Fine Wine Challenge.Mr. Wan Shoupeng, Chairman of Dynasty, concluded, “Looking ahead to 2026, the Group will continue to focus on market and consumer demand, reinvent consumption scenarios and promote product quality. At the same time, the Group will continue to innovate marketing strategies to stimulate brand vitality, further expand the market share of Dynasty’s products, strengthen Dynasty’s brand image as a representative of domestic wines, and set a benchmark for the Chinese wine industry, with the aim of bringing Dynasty’s superior wines to more consumers in the PRC. The Group will continue to uphold quality, seize the development trend of low-alcohol and younger consumer markets, and proactively develop new marketing prospects through innovation in products categories and consumption scenarios.”About Dynasty Fine Wines Group LimitedDynasty Fine Wines Group Limited was listed on the Main Board of The Stock Exchange of Hong Kong Limited with the stock code 00828 on 26 January 2005. Founded in 1980, Dynasty is the premier grape winemaker in China. It is principally engaged in the production and sale of grape wine products under its reputable “Dynasty” brand. Dynasty is the first Sino-foreign joint venture wine company in China with Tianjin Food Group Limited and the French grape wine giant, Remy Cointreau, as its current major shareholders. The Group produces and sells more than 100 grape wine product series, and introduces imported wine products, providing high-quality and value-for-money grape wines to the full range of consumer groups in China.For media enquiries:Strategic Financial Relations (China) LimitedMs. Anita Cheung Tel: 2864 4827Ms. Gianna Ye    Tel: 2864 4837Ms. Hazel Ye     Tel: 2864 4893Ms. Chloe Lyu    Tel: 2864 4835Email: sprg-dynasty@sprg.com.hk Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

อ่านเพิ่มเติม

HONG KONG, Mar 26, 2026 - (ACN Newswire via SeaPRwire.com) - The Census and Statistics Department today released the latest external merchandise trade statistics. In February 2026, the total value of merchandise exports increased by 24.7% year-on-year to $408.8 billion. For the first two months of 2026, the total value of exports of goods amounted to $928.3 billion, marking an increase of 29.6% from the same period of last year.Hong Kong Trade Development Council’s Director of Research Bruce Pang said, over the past few months, Hong Kong’s external trade has continued to exhibit clear growth momentum. Although global geopolitical conditions remain tense, underlying demand from the Chinese Mainland and major overseas markets has remained resilient. We maintain a positive outlook, yet remain cautious in regard to Hong Kong’s trade performance.”HKTDC Media Room: https://mediaroom.hktdc.com/enMedia enquiriesPlease contact the HKTDC’s Communications & Public Affairs Department:Jane CheungTel: (852) 2584 4137Email: jane.mh.cheung@hktdc.org Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

อ่านเพิ่มเติม

NEW YORK, N.Y., Mar 26, 2026 - (ACN Newswire via SeaPRwire.com) - OpenClawd AI today released a security-focused platform update that adds automated skill vetting, verified installer sourcing, and runtime sandboxing to its managed OpenClaw hosting service. The update responds to two converging threats targeting users of the open-source AI agent formerly known as Clawdbot and Moltbot: a large-scale malware campaign inside the official OpenClaw skill marketplace, and a parallel wave of counterfeit installation packages being promoted through search engine results.The numbers are bad enough on their own. Together, they describe a supply chain that is actively hostile to casual users.One in Eight OpenClaw Skills Is Confirmed MaliciousIndependent security researchers recently completed an audit of the ClawHub skill marketplace — the primary distribution channel for third-party OpenClaw plugins. Out of 2,857 published skills, 341 were confirmed as malicious. That is approximately 12% of the entire marketplace.The findings include:Keyloggers and credential stealers deployed through skills that appear to offer legitimate productivity featuresSilent data exfiltration — one widely-downloaded skill was found to instruct the OpenClaw agent to execute curl commands that sent user data to an external server without any notification or consent promptPrompt injection payloads embedded in skill descriptions, designed to override the agent’s safety guidelines and force execution of unauthorized commandsPlaintext credential exposure — a separate audit found that over 280 additional skills were leaking API keys, tokens, and passwords in their source codeA major cybersecurity firm tested a specific ClawHub skill and published the results: nine security findings, including two critical and five high-severity issues. The skill functioned as what the researchers called “functionally malware.” The most widely-downloaded malicious skill on ClawHub was a cryptocurrency stealer.Fake OpenClaw Installers Are Being Promoted by Search EnginesThe marketplace problem is only half the story. A cybersecurity research team discovered that threat actors have published counterfeit OpenClaw installation packages on open-source code repositories. These fake installers mimic the legitimate OpenClaw setup process but instead deliver a malware packer that disables firewall protections and routes network traffic through compromised systems.The attack chain is straightforward: a user searches for “install OpenClaw” or “Clawdbot download.” An AI-powered search engine returns a result linking to the malicious repository. The user follows the instructions. The malware deploys silently.The researcher who discovered the campaign noted that the person who first reported the threat was a technical professional. “If a fellow IT pro is susceptible to this threat,” he said, “then anyone could be.”“There are now two ways to get compromised before you even run your first OpenClaw command,” said Danny Wilson, spokesperson for OpenClawd. “You can install a fake version of the software, or you can install the real version and then add a skill that steals your data. We built this update so that neither path exists on our platform.”What OpenClawd Ships TodayThis update targets both the supply chain and the runtime:Verified installer sourcing — all OpenClawd instances are provisioned from cryptographically signed OpenClaw releases, pulled directly from the official repository. No third-party install paths. No search engine intermediaries.Skill vetting pipeline — third-party skills go through automated static analysis and behavioral testing before activation. Skills flagged for network exfiltration, prompt injection patterns, or credential exposure are blocked by default.Runtime sandboxing — each skill executes in an isolated environment with explicit permission boundaries. A skill that requests network access to an unexpected endpoint triggers a review before execution.Credential isolation — API keys and tokens are stored in encrypted vaults and never exposed in plaintext to skill code or agent logsAutomatic CVE patching — hosted instances track the latest stable OpenClaw release (currently v2026.3.x), with all known vulnerabilities patched before deploymentOpenClawd does not operate its own skill marketplace. Skills available on hosted instances are drawn from the official ClawHub repository after passing the vetting pipeline described above.OpenClawd is not affiliated with the OpenClaw open-source foundation, OpenAI, Peter Steinberger, or any third-party security research firm cited in this release. It is an independent platform built on the open-source Clawdbot codebase. The open-source project remains free at github.com/openclaw/openclaw.Pricing starts with a free tier. Paid plans include dedicated compute, priority security patching, and uptime monitoring. Deploy a secure OpenClaw instance at https://openclawd.ai.Contact:Email: support@openclawd.ai  Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

อ่านเพิ่มเติม

Development Highlights- During the Year, the Group had 4 innovative products approved for marketing by the NMPA, namely, Saitanxin(R) (Culmerciclib Capsules), Hernexeos(R) (Zongertinib Tablets), Putanning(R) (Meloxicam Injection (II)) and Anqixin(R) (Recombinant Human Coagulation Factor VIIa N01 for Injection).- In 2025, the Group’s sales of innovative products reached RMB 15.22 billion, representing a year-on-year increase of 26.2%. In addition, the Group has established multiple R&D centers in Shanghai, Nanjing, Beijing, Guangzhou, and other cities, and has successfully built diversified innovative technology platforms covering small molecules, protein degraders, siRNA, monoclonal/bispecific antibodies, antibody-drug conjugates (ADC), inhalable formulations, transdermal patches and other fields.- As at 31 December 2025, the Group had a total of 39 innovative oncology drug candidates, 10 innovative liver/cardiometabolic drug candidates, 14 innovative respiratory/autoimmune drug candidates, and 6 innovative surgery/analgesia drug candidates in the process of clinical trial application or above. Of these, 1 innovative oncology drug candidate and 2 innovative surgery/analgesia drug candidates are in the marketing application stage; and 13 innovative oncology drug candidates, 1 innovative liver/cardiometabolic drug candidate, 5 innovative respiratory/autoimmune drug candidates, and 1 innovative surgery/analgesia drug candidate are in Phase III clinical trials. Also, 9 innovative oncology drug candidates, 6 liver/cardiometabolic drug candidates, 5 innovative respiratory/autoimmune drug candidates, and 2 innovative surgery/analgesia drug candidates are in Phase II clinical trials. In addition, the Group had a total of 16 innovative oncology drug candidates, 3 innovative liver/cardiometabolic drug candidates, 4 innovative respiratory/autoimmune drug candidates, and 1 innovative surgery/analgesia drug candidate in Phase I clinical trials.- Focus V(R) (Anlotinib Hydrochloride Capsules) is a novel small molecule multi-target tyrosine kinase inhibitor that has been approved for 10 indications. It has several new indications currently in Phase III clinical studies, including first-line non-squamous non-small cell lung cancer and first-line pancreatic cancer, with plans to gradually submit marketing applications within the next two years.- From 2023 to 2025, the Group obtained marketing approval for 7 national category 1 innovative oncology drugs, namely, Saitanxin(R) (Culmerciclib capsule), Hernexeos(R) (Zongertinib table), Yilishu(R) (Efbemalenograstim alfa Injection), Andewei(R) (Benmelstobart Injection), Anboni(R) (Unecritinib Fumarate Capsules), Anluoqing(R) (Envonalkib Citrate Capsules), and Anfangning(R) (Garsorasib Tablets). It also obtained marketing approval for 4 oncology biosimilars, including Anbeisi(R) (Bevacizumab Injection), Delituo(R) (Rituximab Injection), Saituo(R) (Trastuzumab for Injection), and Paletan(R) (Pertuzumab Injection). The sales volume of these products accelerated rapidly in 2025, and they have become important contributors to the Group’s revenue growth.- Tianqing Ganmei(R) (Magnesium Isoglycyrrhizinate Injection) is the fourth-generation of glycyrrhizic acid preparation that has been approved for 3 indications. During the Year, the Group made efforts to strengthen academic promotion, expanding doctor coverage and gaining recognition from experts through academic conferences at all levels, while vigorously exploring new patients to expand into new markets, and actively promoting retrospective research to provide more academic evidence for its clinical use.- TQC3721 (PDE3/4 inhibitor) is a dual PDE3/4 inhibitor currently undergoing Phase III clinical trials in China for the treatment of moderate to severe chronic obstructive pulmonary disease (COPD). The Group is developing a variety of dosage forms of TQC3721: a suspension for inhalation is in Phase III clinical trials, and an inhaled dry powder formulation is in Phase II clinical trials. The different dosage forms are expected to further enhance patient compliance.- Zepolas(R)/Debaian(R) (Flurbiprofen Cataplasms) is the first domestically produced cataplasms approved for marketing in China, ranking first in the market share of topical analgesia for many years. The Group focuses on the development of highpotential regions, further expanding its market coverage and gradually increasing its production capacity to meet the booming market demand, driving the sustained rapid sales growth of Zepolas/Debaian. The second-generation flurbiprofen patch developed by the Group is expected to be approved for marketing within one year. With formulation enhancements, the second-generation product can significantly improve the transdermal absorption of the drug and enhance the adhesiveness of the plaster, thereby improving patient compliance.HONG KONG, Mar 26, 2026 - (ACN Newswire via SeaPRwire.com) – Sino Biopharmaceutical Limited (“Sino Biopharmaceutical” or the “Company”, together with its subsidiaries, the “Group”) (HKEX stock code:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its audited financial results for the year ended 31 December 2025 (the “Year”).During the Year, the Group's revenue increased by approximately 10.3% to approximately RMB31.83 billion. Profit attributable to owners of the parent from continuing operations (as reported) was approximately RMB2.34 billion, a year-on-year increase of approximately 22.0%. Basic earnings per share attributable to owners of the parent from the continuing operations were approximately RMB13.02 cents, an increase of approximately 24.0% over last year. Underlying profit attributable to owners of the parent totaled approximately RMB4.54 billion, a year-on-year increase of approximately 31.4%. The Group’s liquidity remained strong, with cash and bank balances classified as current assets of approximately RMB12.18 billion, bank deposits classified as non-current assets of approximately RMB10.25 billion, wealth management products of approximately RMB10.56 billion in total, and total fund reserves of approximately RMB32.99 billion for the Year.The Board of Directors has recommended a final dividend payment of HK5 cents per share (2024: HK4 cents). Together with an interim dividend of HK5 cents already paid, the total dividend for the year amounts to HK10 cents (2024: HK7 cents).Sales: Innovation-driven growth fuels sustained sales momentumDuring the Year, the Group consistently increased investments to enhance R&D quality and efficiency, which led to a marked strengthening of R&D capabilities, driving sustained sales revenue growth and delivering substantial results. Sales of innovative products increased by 26.2% year-on-year to approximately RMB15.22 billion, accounting for approximately 47.8% of the Group’s revenue. If the sales is categorized by therapy field, sales of oncology drugs increased by 22.8% year-on-year to approximately RMB13.18 billion, accounting for approximately 41.4% of the Group's revenue. Sales of surgical/analgesic medications increased by 12.8% year-on-year to approximately RMB5.03 billion, accounting for approximately 15.8% of the Group's revenue.In the field of oncology, the Group has a comprehensive layout in non-small cell lung cancer (NSCLC), covering the full-line treatment of multiple subtypes. Focus V(R) (Anlotinib Hydrochloride Capsules) has been approved for 10 indications, and several new indications are currently in the marketing application or Phase III clinical trial stage. Its combination therapy has demonstrated superior efficacy in the treatment of lung cancer. From 2023 to 2025, the Group obtained approval for and launched a total of 7 national category 1 innovative oncology drugs and 4 oncology biosimilars. The sales volume of these products accelerated rapidly in 2025, and they have become important contributors to the Group’s revenue growth.In the field of surgery/analgesia, Zepolas(R)/Debaian(R) (Flurbiprofen Cataplasms) have ranked first in market share of topical analgesia for many years. The second-generation flurbiprofen patch is anticipated to receive marketing approval within the year and is expected to strengthen its market leadership through this dosage form upgrade. Meanwhile, Putanning(R) (Meloxicam Injection (II)), China’s first once-daily long-acting analgesic NSAIDs injection, was approved for marketing by the NMPA and the FDA in May 2025 and has been included in the NRDL in 2025. It is expected to become another blockbuster product for the Group in pain management area.R&D: Technology-driven advancements significantly enhance R&D quality and efficiency R&D innovation has always been the key driving force of the Group. The Group has established multiple R&D centers in places including Shanghai, Nanjing, Beijing, and Guangzhou, and has successfully built diversified innovative technology platforms covering such fields as small molecules, protein degraders, siRNA, monoclonal/bispecific antibodies, antibody-drug conjugates (ADC), inhalation formulations, and transdermal patches. For the year ended 31 December 2025, the Group’s total R&D investment amounted to approximately RMB 6.32 billion, accounting for approximately 19.8% of Group revenue.The Group also attaches tremendous importance to the protection of intellectual property rights and actively files patent applications to enhance its core competitiveness. During the Year, the Group filed 1,167 new patent applications and received 273 patent grants. As at the end of the Year, the Group had accumulated 5,724 valid patent applications and obtained 2,120 valid patent grants.Prospects: Focusing on innovation and firmly promoting internationalization strategyLooking ahead, the Group will continue to focus on innovation and remain deeply committed to four core therapeutic areas – oncology, liver / cardiometabolic diseases, respiratory/autoimmune diseases, and surgery/analgesia. It will leverage AI to deeply empower the entire R&D process and continuously strengthen its R&D and innovation capabilities to drive steady business growth. Over the next three years (2026-2028), the Group’s innovation pipeline is expected to experience another wave of explosive growth, with nearly 20 national category 1 innovative drugs expected to be approved for marketing, including multiple blockbuster products with first-in-class (FIC) and best-in-class (BIC) potential. It is expected that by the end of 2028, the total number of innovative products launched by the Group will be around 40, positioning them as the core driver of business growth.At the same time, the Group will firmly advance its internationalization strategy. In February 2026, the Group announced that it had granted Sanofi an exclusive worldwide license to develop, manufacture, and commercialize Rovadicitinib, with the right to receive payments of up to US$1.53 billion, plus tiered royalties of up to double digits based on annual net sales of Rovadicitinib. Going forward, out-licensing will become another important source of revenue for the Group, continuously injecting strong, new momentum into its performance growth and formally launching a second growth curve supported by revenue from internationalization. In addition, the Group remains committed to adhering to the "win-win cooperation" philosophy and is dedicated to building an open and diverse innovation ecosystem. Through in-depth cooperation with the world's leading pharmaceutical companies, biotechnology firms and scientific research institutions, the Group is accelerating the aggregation of high-quality global resources, promoting the co-creation and sharing of innovative outcomes, and continuously strengthening its market leadership. Through the integration of high-quality resources such as LaNova Medicines and Hygieia, the Group has significantly strengthened its R&D capabilities in cutting-edge fields, including tumor immunology and siRNA.Looking ahead, the Group will continue to drive innovation through its dual engines of internal R&D and strategic cooperation, accelerate its development through internationalization, and make steady progress towards its strategic goal of becoming a world-class innovative pharmaceutical company.For detailed information on the Group’s results for the Year, please refer to the official announcements uploaded by the Group to the Hong Kong Stock Exchange website and its official website.About Sino Biopharmaceutical Limited (HKEX:1177)Sino Biopharmaceutical Limited, together with its subsidiaries, is a leading, innovative R&D-driven pharmaceutical group in China. Its business covers the entire industrial chain, including R&D platforms, intelligent manufacturing, and a robust sales system. Its products encompass a wide range of biologics and chemical drugs, with a strong presence in four core therapeutic areas: oncology, liver/cardiometabolic diseases, respiratory/autoimmune diseases, and surgery/analgesia. The company was listed on the Hong Kong Stock Exchange in 2000, was included as a constituent of the MSCI China Index in 2013, became a constituent of the Hang Seng Index in 2018, and was added to the Hang Seng Stock Connect Biotech 50 Index and the Hang Seng China (Hong Kong-listed) 25 Index in 2020. The company has been named among the "Top 50 Global Pharmaceutical Companies" by the authoritative U.S. magazine Pharm Exec for seven consecutive years, and has been recognized as one of the "Top 50 Best Companies in Asia" by Forbes Asia for three consecutive years.For more information, please visit: www.sbpgroup.com  Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

อ่านเพิ่มเติม

West Palm Beach, FL, Mar 26, 2026 - (ACN Newswire via SeaPRwire.com) - U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA) founded in 1890, today announced the launch of its Global Polo Shirt Campaign, An Icon Born from the Game. The global campaign is a powerful tribute to the iconic polo shirt's authentic sports origins and its evolution into one of the world's most enduring style essentials.U.S. Polo Assn. Global Brand Ambassador, 6-goal American professional polo player Nico Escobar takes in the game atop his equine partner, wearing polo whites and a classic navy U.S. Polo Assn. polo shirt, An Icon Born from the GameU.S. Polo Assn. models in polo shirts at the Spring-Summer 2026 Global Collection Photoshoot in Charleston, South Carolina‘The Polo Shirt: An Icon Born From the Game' campaign imagery featuring U.S. Polo Assn. modelsThe polo shirt's beginning was born on the polo fields, shaped by motion, competition, and the spirit of the game for which it was named. From its earliest days, the polo shirt was designed with purpose, worn by players seeking performance on the polo fields. Today, U.S. Polo Assn. celebrates this timeless favorite, not just as a fashion item, but as an icon born from sport and carried forward through generations of players and consumers all over the world.The polo shirt is one of the most iconic essentials dating back over 100 years, notable for its unique fusion of sport and style. Originally designed with breathable pique knit, a soft collar, and lightweight construction to meet the demands of competitive sports, it has evolved into a timeless essential, suitable for casual elegance and leisurewear.The polo shirt traces its origins to polo players, where it was created out of necessity for the sport. Polo players modified long‑sleeved cotton shirts to better handle heat, movement, and wind while playing. These functional, sport‑driven adaptations represent the earliest form of what would become the polo shirt. In the early 20th century, polo players helped formalize these functional elements as the sport gained popularity, reinforcing the shirt's connection to the sport and its functional design.Over the years, the polo shirt became a cornerstone of casual sportswear around the world, symbolizing preppy style, luxury leisure culture, and contemporary athleisure, seamlessly transitioning from polo fields to college campuses and boardrooms. Its enduring adaptability is demonstrated by distinct reinventions across the decades; the ability to evolve has ensured the polo shirt's lasting relevance and cultural significance.As the official sports brand of the USPA, founded in 1890 and one of the oldest sports governing bodies in the United States, U.S. Polo Assn. occupies an authentic place in the history of the polo shirt."The polo shirt's DNA is deeply rooted in the inspirational sport that inspired it," said J. Michael Prince, President and CEO of USPA Global, the company that manages and markets the multi-billion-dollar, global U.S. Polo Assn. brand. "With An Icon Born from the Game, we're honoring a legacy that began on the field and continues to shape how polo players, sports fans, and consumers all over the world live, move, and express themselves today, and for future generations."An Icon Born from the Game reinforces that legacy by connecting the polo shirt's origins in the sport, while celebrating its place in modern culture."The polo shirt was designed for the game with a real purpose on the field, but it's also what I wear off the field to go out to dinner or hang out with friends and family," said Nico Escobar, U.S. Polo Assn. Global Brand Ambassador, 6-goal American professional polo player. "I love that U.S. Polo Assn. understands both the performance aspect and how the polo shirt fits into everyday life.""U.S. Polo Assn.'s authentic connection to the sport and the way it supports the game of polo around the world is why I wear it - both on the field and off," adds Escobar.Global Launch: An Icon Born from the GameLaunching globally across 190 countries in Spring 2026, An Icon Born from the Game will come to life through a coordinated, multi‑channel presence designed to make the U.S. Polo Assn. polo shirt unmistakably visible wherever consumers engage with the sport-inspired brand. In stores, dedicated polo shirt focus areas, including the brand's iconic polo walls, window displays, and visual merchandising moments, will highlight the full range of styles through bold color stories, clear categorization, and campaign signage anchored by the slogan.Across outdoor and print advertising, hero imagery shot on location brings the polo shirt back to the field, reinforcing its authentic connection to the sport, while digital and social media activations extend the story through short‑form content and global storytelling. Together, these touchpoints create a consistent, immersive expression of the polo shirt as a true icon rooted in sport but relevant to everyday life.Further, An Icon Born from the Game is launching around two of the sport's most important events in the United States - the prestigious USPA Gold Cup® and one of the most competitive tournaments in the world, the U.S. Open Polo Championship®, which concludes with the Championship Final on April 26."An Icon Born from the Game is about owning our truth and telling it boldly on a global scale," said Stefanie Coroalles, Vice President, Global Brand Marketing. "The Global Polo Shirt Campaign brings together heritage, product, and self-expression, showing how the polo shirt moves effortlessly from sport to everyday life.""This launch is a proud moment for us, one that brings our heritage to life in a way that feels modern, visible, and unmistakably U.S. Polo Assn.," adds Coroalles.Product Pillars: Play It Your Way"Every U.S. Polo Assn. polo shirt is designed with intention by balancing style, comfort, function, and authentic sport details," said Brian Kaminer, Senior Vice President, Brand and Product Development. "From heritage-inspired construction to modern performance fabrics, our U.S. Polo Assn. collections reflect how the polo shirt continues to evolve while staying true to its sports roots."The global polo shirt campaign showcases the versatility of the icon through five distinct expressions that give the consumer the opportunity to "Play It Your Way" when styling with the polo shirt.Play It Sporty is the polo shirt that carries the legacy of U.S. Polo Assn. in every stitch. Featuring authentic detailing, iconic branding, and sport-inspired elements, this timeless silhouette connects directly to the game that started it all. Official crests, classic cuts, and traditional design details celebrate the sport of polo's history and the brand's deep-rooted heritage.Play It Classic is the polo shirt for the moments that make up everyday life. Clean, comfortable, and easy to style, it's the go-to option when you want something that always works. Designed to be worn again and again, it fits seamlessly into any routine, whether casual, relaxed, or slightly dressed up.Play It in Motion with the performance polo shirt engineered for action. Advanced technical fabrics deliver moisture-wicking comfort, breathability, and stretch that moves with you throughout the day. Designed for polo players on the field or in life in motion, it balances durability and function with a sharp, modern look.Play It Bold is the fashion polo shirt built for self-expression. Defined by confidence and style, this version brings personality and freedom to a familiar icon. Worn casually or styled with intention, it shows how versatile the polo shirt can be when it's shaped by confidence and worn on an individual's own terms.Play It Elevated is the premium polo shirt made for moments that call for refinement. Crafted with elevated materials and thoughtful detailing, it offers a polished look without feeling formal. Clean lines and a thoughtful fit create a composed yet confident style that balances ease with sophistication.U.S. Polo Assn.'s seasonal polo shirts are offered across men's, women's, and kids' collections in an expansive range of fabrics, finishes, and colors - from classic neutrals to vibrant hues. Updated designs feature textured ribs, subtle patterns, and elevated construction details, finished with the brand's signature Double Horsemen logo - a mark of authenticity and a symbol of the sport.U.S. Polo Assn. continues to incorporate products aligned with its global sustainability program, USPA Life, reflecting the brand's commitment to responsible sourcing and long-term environmental initiatives. The USPA Life Polo Shirt, arriving in stores Spring 2027, builds on U.S. Polo Assn.'s most iconic style, designed with thoughtfully chosen, preferred materials that reflect the brand's commitment to improving the global footprint of this iconic staple. From 100% preferred cotton fabric to the finishing details like buttons and thread, each element has been selected to reduce impact while preserving the classic look, comfort, and quality customers expect from a U.S. Polo Assn. polo shirt.U.S. Polo Assn. apparel and accessories are available in U.S. Polo Assn. stores and online at uspoloassnglobal.com.About U.S. Polo Assn. and USPA GlobalU.S. Polo Assn. is the official sports brand of the United States Polo Association (USPA), the largest association of polo clubs and polo players in the United States, founded in 1890. With a multi-billion-dollar global footprint and worldwide distribution through more than 1,200 U.S. Polo Assn. retail stores as well as thousands of additional points of distribution, U.S. Polo Assn. offers apparel, accessories, and footwear for men, women, and children in more than 190 countries worldwide. The brand sponsors major polo events around the world, including the U.S. Open Polo Championship®, held annually at NPC in The Palm Beaches, the premier polo tournament in the United States. Historic deals with ESPN in the United States, TNT and Eurosport in Europe, and Star Sportsin India now broadcast several of the premier polo championships in the world, sponsored by U.S. Polo Assn., making the thrilling sport accessible to millions of sports fans globally for the very first time.U.S. Polo Assn. has consistently been named one of the top global sports licensors in the world alongside the NFL, PGA Tour, and Formula 1, according to License Global. In addition, the sport-inspired brand is being recognized internationally with awards for global growth and sports content. Due to its tremendous success as a global brand, U.S. Polo Assn. has been featured in Forbes, Fortune, Modern Retail, and GQ as well as on Yahoo Finance and Bloomberg, among many other noteworthy media sources around the world. For more information, visit uspoloassnglobal.com and follow @uspoloassn.USPA Global is a subsidiary of the United States Polo Association (USPA) and manages the multi-billion-dollar sports brand, U.S. Polo Assn. USPA Global also manages the subsidiary, Global Polo, which is the worldwide leader in polo sport content. To learn more, visit globalpolo.com or Global Polo on YouTube.For Additional Information, Contact:Stacey Kovalsky - VP, Global PR and CommunicationsPhone +954.673.1331 - E-mail: skovalsky@uspagl.comKaela Drake - Senior PR and Comms SpecialistPhone +561.530.5300 - E-mail: kdrake@uspagl.comSOURCE: U.S. Polo Assn. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

อ่านเพิ่มเติม

Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - March 26, 2026) - Casa Minerals Inc. (TSXV: CASA) (OTCQB: CASXF) (FSE: 0CM) (the "Company" or "Casa") is pleased to announce that it has received a large dataset of historic drill hole information from the Congress Gold Mine Project in Yavapai County, Arizona, USA. Comprehensive desktop technical studies integrating this data with the Company's own 2022 drilling campaign have resulted in the identification and delineation of three distinct priority exploration zones that will form the basis of the 2026 field and drilling program.HIGHLIGHTSReceipt of a large historic drill hole database greatly expanding the geological model for the Congress Gold Mine Project3D modelling of over 100 historic and recent drill holes confirms strong structural integrity and continuity of the gold-bearing vein systemsThree distinct exploration zones classified: Echo Bay Exploration Zone (~750m x 1,000m), Malartic Exploration Zone (~450m x 1,150m), and New Congress Niagara Exploration Zone (~800m x 1,000m)Echo Bay Exploration Zone designated highest priority target based on historic drill density and potential for expanded mineralization envelopeHistoric drill intercepts include highlights such as 1.2m @ 43.88 g/t Au, 2.0m @ 21.88 g/t Au, 3.3m @ 27.13 g/t Au, and 11.4m @ 4.81 g/t Au within the Echo Bay ZoneCongress Gold Mine Project is fully permitted with excellent road access and proximity to an experienced regional labor forceCompany geologists and field personnel are being mobilized for initial site preparation and drill program setupHISTORIC DRILL DATABASE COMPILATIONCasa Minerals is pleased to announce the receipt of a comprehensive dataset of historic drill hole collars, surveys, and assay records from the Congress Gold Mine Project. This data was compiled from exploration programs conducted by previous operators -- most notably Echo Bay Mines Ltd. -- during the 1980s through the early 1990s. The database encompasses a significant number of drill holes distributed across the project area, substantially expanding the known geological framework of the property.Historic exploration at the Congress Gold Mine was conducted during a period when gold market conditions were materially lower than today's environment, which directly influenced the selection criteria and cut-off grades used by previous operators. Consequently, the historic programs focused predominantly on higher-grade gold intersections, and many lower-grade vein intercepts that may be economically significant at current gold prices were not assigned the same level of analytical priority. Casa believes this creates a meaningful opportunity to reinterpret the mineralization system with a lower economic threshold, logically expanding the dimensions of the mineralization envelope that will be targeted in the forthcoming drilling season.Important Disclosure: The historic drill hole results referenced in this news release were collected and reported by previous operators under practices that predate current NI 43-101 standards. These results are disclosed solely for contextual and geological interpretation purposes. They have not been verified by a current Qualified Person, do not conform to NI 43-101, and are not classified as current mineral resources or mineral reserves. A Qualified Person has not done sufficient work to classify the historic results as current mineral resources or mineral reserves, and Casa is not treating them as such.THREE-DIMENSIONAL MODELLING AND VEIN SYSTEM VALIDATIONDesktop technical studies have included rigorous 3D modelling of all available drill hole data using industry-standard geological modelling software. The resulting three-dimensional representation of the drill hole database, illustrated in Figure A below, demonstrates the remarkable density of historic drill coverage across the project and confirms the structural coherence and continuity of the principal gold-bearing vein systems.The 3D model was constructed using NAD83 / UTM Zone 12N coordinates and captures drill holes ranging from surface to depths approaching 600 metres below ground elevation. The model reveals that:The dominant vein systems exhibit strong northeast-southwest structural orientation, consistent with the principal fault architecture identified on surfaceThe alignment and attitude of vein structures intercepted in the Company's 2022 confirmatory drilling campaign correlate with high fidelity to those projected from the historic drill hole database, validating the overall geological modelThe 2022 drilling campaign identified additional vein structures not captured in the historic database, indicating that the current geological model is likely incomplete and that the total mineralized footprint may be materially larger than previously understoodIncorporating lower-grade vein intercepts -- previously deprioritized by historic operators under lower gold price conditions -- into the mineralization envelope substantially increases the aggregate target volume for future drillingFigure A: Four-panel 3D presentation of historic and recent drill hole collars and traces, Congress Gold Mine Project. Views from west (upper left), east (upper right), oblique (lower left), and plan (lower right). Coordinate system: NAD83 / UTM Zone 12N. The high density of drill traces illustrates the extensive historic exploration coverage across the project area. Pink/magenta traces represent historic drill holes; black traces represent more recent drilling. Purple lines denote projected vein orientations.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/1750/290037_3e63fd76341e7b14_001full.jpgTHREE PRIORITY EXPLORATION ZONES -- 2026 PROGRAM BASISDetailed integration of the historic drill database with geological mapping, vein system mapping conducted in 2022, and structural interpretation has enabled Casa to formally classify three distinct priority exploration zones within the Congress Gold Mine Project. The classification of each zone reflects the combination of historic drill density, vein system geometry, and the nature of the gold mineralization documented to date. Figures 1 through 4 present these zones in their regional and local contexts.Figure 1: Regional overview map of the Congress Gold Mine Project showing principal vein systems (red dashed), fault corridors (blue dashed), shaft locations (Shafts 1 through 6), historic stope outlines (yellow, 1959-1987), patented claim and BLM claim outlines, and the location of the three principal exploration zones. The project is situated in Yavapai County, Arizona.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/1750/290037_3e63fd76341e7b14_002full.jpgEcho Bay Exploration Zone -- Highest Priority TargetThe Echo Bay Exploration Zone, measuring approximately 750 metres by 1,000 metres, is the largest and most intensively drilled zone on the property. It encompasses the historic non-NI 43-101 resource outline that was previously defined by Echo Bay Mines and represents the core of the historic gold-producing system at Congress. The zone is bounded by the principal northeast-trending veining corridors and is cut by northwest-trending fault structures that locally displace but do not terminate the mineralized vein arrays.As illustrated in Figure 2, the Echo Bay Exploration Zone hosts a dense cluster of historic drill hole intercepts distributed across the full extent of the zone. The drill hole collars and assay intercepts depicted in the figure provide compelling evidence for broad, zone-scale gold mineralization. Notably, the higher-grade intercepts are concentrated along the principal vein corridors while lower-grade disseminated and stockwork gold is documented in the intervening ground. This spatial distribution is characteristic of orogenic gold systems and is consistent with the geological setting at Congress.Selected historic drill intercepts within the Echo Bay Exploration Zone include:1.2m @ 43.88 g/t Au -- exceptional high-grade intercept within the principal vein corridor3.3m @ 27.13 g/t Au -- high-grade intercept demonstrating vein width and continuity2.0m @ 21.88 g/t Au -- high-grade vein intercept in the central portion of the zone2.4m @ 19.03 g/t Au -- confirming strong grade continuity along strike11.4m @ 4.81 g/t Au -- broad, elevated-grade intercept indicative of wide mineralization envelopes within the vein system1.5m @ 15.28 g/t Au -- demonstrating high-grade vein core and broader lower-grade haloes2.0m @ 12.19 g/t Au and 7.3m @ 11.00 g/t Au -- further confirming grade and continuity of the principal vein arrays3.1m @ 11.19 g/t Au and 2.0m @ 15.63 g/t Au -- documented in the southwestern portion of the zone, indicating lateral continuityGiven the historic drill density, the documented grade profile, and the alignment of the 2022 confirmatory drilling with the historic vein model, the Echo Bay Exploration Zone has been assigned the highest exploration priority for the 2026 program. The Company views the zone as offering the clearest near-term pathway to NI 43-101 resource delineation.Figure 2: Detailed plan map of the Echo Bay Exploration Zone (~750m x 1,000m), Congress Gold Mine Project. Shown are historic drill hole intercepts (brown dots annotated with interval length in metres and gold grade in g/t), principal vein system traces (red dashed), fault corridors (blue dashed), historic stope outlines (yellow), shaft locations, and the historic non-NI 43-101 resource outline (red hatch). Selected intercepts include 1.2m @ 43.88 g/t Au, 3.3m @ 27.13 g/t Au, 11.4m @ 4.81 g/t Au, and 2.4m @ 19.03 g/t Au, among numerous others. To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/1750/290037_3e63fd76341e7b14_003full.jpgMalartic Exploration ZoneThe Malartic Exploration Zone covers an area of approximately 450 metres by 1,150 metres and is situated to the south and southeast of the Echo Bay Exploration Zone. The zone is named after the "Malartic-style" stratabound and vein-hosted gold mineralization that has been documented in this area of the project. Historic shaft locations CGC-003 and CGC-004 are located within this zone, providing direct underground access for potential future development.The Malartic Exploration Zone is characterized by multiple subparallel northwest-striking vein sets that have been intercepted in a series of shallow to moderate-depth drill holes. The vein system includes documented vein widths of 27 feet, 38 feet, and 55 feet (as labelled on Figure 3), indicating substantial structural corridors capable of hosting economically significant gold mineralization.Representative historic drill intercepts within the Malartic Exploration Zone include:3.6m @ 0.74 g/t Au and 10.3m @ 1.73 g/t Au -- broad lower-grade intercepts within the principal vein corridor demonstrating wide mineralization envelopes10.36m @ 1.41 g/t Au and 8.1m @ 3.53 g/t Au -- moderate-grade intercepts confirming continuity of the vein arrays7.7 @ 3.56 g/t Au and 8.1m @ 2.53 g/t Au -- further demonstrating consistent grade within vein-hosted mineralization3.2m @ 7.72 g/t Au and 2.8m @ 9.41 g/t Au -- higher-grade intercepts at the northern margin of the zone (shared boundary with the Echo Bay Zone)The Malartic Exploration Zone is relatively underexplored compared to the Echo Bay Zone, and the relatively sparse drill coverage suggests significant upside potential for zone expansion with systematic drilling.Figure 3: Detailed plan map of the Malartic Exploration Zone (~450m x 1,150m), Congress Gold Mine Project. Shown are historic drill hole intercepts (annotated with gold values), principal vein system traces, shaft locations including CGC-003 and CGC-004, historic stope outlines, and documented vein widths of 8.2m, 11.6m, and 16.8m.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/1750/290037_3e63fd76341e7b14_004full.jpgNew Congress Niagara Exploration ZoneThe New Congress Niagara Exploration Zone, measuring approximately 800 metres by 1,000 metres, is the northernmost of the three classified exploration zones and is situated along a structurally distinct corridor characterized by the northwest-striking New Congress-Niagara fault system. This zone encompasses historic Shaft 1 as well as drill holes CGC-008, CGC-009, and CGC-010 from the Company's 2022 exploration program.The 2022 drilling in this zone identified four discrete veins with widths ranging from 49.5 feet to 206 feet -- a notably wide structural corridor. These widths are illustrated in Figure 4 as Vein 49.5 ft, Vein 55 ft, Vein 70.5 ft, and Vein 206 ft. The scale of these structural features highlights the potential for significant bulk-tonnage style mineralization within this zone, distinct from the higher-grade but narrower veins documented in the Echo Bay Zone.Critically, the 2022 drilling at the New Congress Niagara Zone identified several vein structures that are not represented in the historic drill database, reinforcing the Company's view that the existing geological model incompletely captures the full scope of the vein system. This structural incompleteness, combined with the relatively limited historic drill coverage of this zone, underscores its exploration potential.Figure 4: Detailed plan map of the New Congress Niagara Exploration Zone (~800m x 1,000m), Congress Gold Mine Project. Shown are drill hole locations from the 2022 exploration program (CGC-008, CGC-009, CGC-010) alongside Shaft 1, with identified vein widths of 49.5 ft, 55 ft, 70.5 ft, and 206 ft. The purple outline denotes the exploration zone boundary.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/1750/290037_3e63fd76341e7b14_005full.jpgPROJECT STATUS AND 2026 FIELD PROGRAMThe Congress Gold Mine Project is fully permitted for exploration and mining activities in Yavapai County, Arizona. The property benefits from:Fully permitted status: All necessary exploration and access permits are in place, enabling rapid mobilization of field crews and drilling equipmentExcellent road access: Paved and maintained road access to the property boundary facilitates cost-effective equipment and supply logisticsExperienced regional labor force: The Yavapai County region has a well-established mining and exploration workforce with proven experience in gold exploration projects of this typeInfrastructure: Existing shaft infrastructure and historic workings provide geological reference points and potential future development opportunitiesThe Company is currently mobilizing a team of geologists and field personnel to the Congress Gold Mine Project for initial site preparation, geological review, and establishment of the field infrastructure required for the 2026 drilling program. Detailed drill program parameters, including planned hole locations, depths, and targeting rationale, will be provided in a subsequent technical news release.MANAGEMENT COMMENTARY"The receipt of this historic drill database is a genuinely significant development for Casa Minerals," stated Farshad Shirvani, President and CEO. "For the first time, we now have a comprehensive view of the full scope of historic exploration at Congress, and what we see is highly encouraging. The 3D model clearly validates our 2022 findings and demonstrates that the gold system is both continuous and larger than historic estimates suggested. With gold trading at current levels, the lower-grade vein intercepts that were historically deprioritized now become compelling exploration targets in their own right. The Echo Bay Zone, with intercepts like 1.2m @ 43.88 g/t and 11.4m @ 4.81 g/t, gives us a very strong foundation from which to build a modern NI 43-101 resource. We are mobilizing our team and look forward to reporting our first drill results from the 2026 season."QUALIFIED PERSONMr. Erik Ostensoe, P.Geo., a Director and Chief Geologist of the Company, a Qualified Person as defined by National Instrument 43-101 - Standards of Disclosure for Mineral Projects, has reviewed and approved the scientific and technical disclosure in this news release.ABOUT CASA MINERALS INC.Casa Minerals Inc. is a mineral exploration company focused on gold, copper, and strategic minerals exploration in North America. The Company holds a 90% interest in the historic Congress Gold Mine in Arizona and is advancing multiple projects in British Columbia, including the Arsenault copper-gold-silver project. Casa's experienced management team is committed to creating shareholder value through the discovery and development of economic mineral deposits. For more information, please visit: www.casaminerals.comON BEHALF OF THE BOARD OF DIRECTORSFarshad Shirvani, M.Sc. GeologyPresident, CEO and DirectorFor more information, please contact:Casa Minerals Inc.Farshad Shirvani, President & CEOPhone: (604) 678-9587Email: contact@casaminerals.comCAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTSThis news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements regarding: the Company's exploration plans and programs for 2026; anticipated drilling activities at the Congress Gold Mine Project; the classification and prioritization of exploration zones; expectations regarding resource definition and the potential to advance the project to NI 43-101 compliant standards; interpretations of historic drill data and 3D geological models; mineralization potential and domain expansion; and mobilization of field personnel. Forward-looking information is based on the opinions and estimates of management at the date the information is made and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated. Such factors include, without limitation: uncertainties regarding exploration results; risks related to the accuracy and completeness of historic data; the inability to verify historic assay results; variations in mineralization and grade; the speculative nature of mineral exploration; challenges in obtaining required permits and approvals; fluctuations in commodity prices; availability of financing; changes in economic and market conditions; environmental and regulatory risks; operating hazards; and other risks inherent in the mineral exploration industry. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/290037 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

อ่านเพิ่มเติม

SINGAPORE, Mar 26, 2026 - (ACN Newswire via SeaPRwire.com) – March 19, AAC Technologies Holdings Inc. (HKEX Stock Code: 2018) held its 2025 Annual Results Announcement Conference in Singapore and reported a strong set of annual results. The Group achieved RMB 31.82 billion in annual revenue, representing a 16.4% year-on-year increase and marking a record high of over RMB 30 billion, with net profit rising 39.8% to RMB 2.51 billion. These results reflect the continued success of the Company’s strategic transformation, with revenue reaching new highs in recent years and net profit delivering sustained double-digit growth.“Pioneering Innovation” and “AI Empowerment” have emerged as the central themes of AAC’s recent developments, driving its strategic transformation from a traditional component supplier to a builder of AI perception infrastructure.In an interview during the conference, AAC’s Chief Financial Officer, Guo Dan, highlighted that the Company’s strategic new business lines — represented by optics and automotive solutions — together with its expansion into high-potential AI sectors such as heat dissipation, robotics, and XR, have become the key growth engines supporting mid-to-long-term sustainable development. This strong momentum is expected to continue unlocking further growth potential in 2026.Looking ahead to 2026, Dan expressed strong confidence. Despite persistent industry volatility, the Group will capitalize on its diversified business portfolio to deliver steady revenue growth, with the growth rate expected to be no lower than that of 2025. At the same time, the gross profit margin is projected to improve steadily from the 22.1% baseline in 2025.( AAC Technologies CFO Guo Dan)1. On the Optics Business: Plastic Lens Gross Margin to Rise to 35%, with Proprietary WLG Technology Reaching Key MilestoneAs a core strategic growth driver, AAC’s optics business (AAC Optics) has achieved rapid development since in 2019. It reported RMB 5.73 billion in revenue in 2025, with a compound annual growth rate (CAGR) exceeding 32% over the past six years, establishing itself as a key pillar of the Group’s overall growth.Dan stated that in 2026, the optics business is expected to deliver steady revenue growth while further improving its gross margin. In 2025, the Company continued to upgrade its mid-to-high-end lens product mix, with the shipments of lens products with 6 or more elements accounting for over 18% of the total and seven-element (7P) lens shipments reaching 15 million units. Building on this foundation, the gross profit margin of plastic lenses is projected to rise from 30% in 2025 to 35% in 2026, reaching a industry-leading level.Notably, AAC has made a significant breakthrough in its globally proprietary Wafer-Level Glass (WLG) lens technology, reaching a key milestone. This advancement not only expands the scope of application scenarios but is also expected to drive a shift in the market landscape traditionally dominated by plastic lenses. Dan added, “In the future, whether in smartphones, automotive solutions, or emerging smart terminal devices, we will see more stable incremental growth that will inject long-term momentum into our business growth.”2. On the Automotive Solution Business: The "Second Growth Engine" Solidifies, with 2026 Revenue Expected to Grow by 15%-20%Through the acquisition of Premium Sound Solutions (PSS), AAC has rapidly established a core platform in the smart automotive solution sector, successfully developing a second growth engine for the Company.Dan revealed that following the acquisition of PSS in 2024 and the acquisitions of Chuguang and PSG in 2025, the Company has become a comprehensive system-level automotive solution provider, expanding its business from smartphones into the entire automotive domain. In 2025, the Company’s automotive acoustics business recorded revenue of RMB 4.12 billion, representing a year-on-year increase of 16.1%. This performance has positioned AAC among the world’s top-tier automotive audio system suppliers, second only to industry leaders such as Harman and Bose.Regarding the 2026 outlook for the automotive acoustics business, Dan stated that the segment is expected to maintain high double-digit growth of 15% to 20%, while keeping the gross margin stable. The Company’s automotive solution business has now achieved broad customer coverage both in China and overseas, including multiple Asian markets. This diversified regional presence is expected to provide steady and reliable support for both revenue and profit growth.3. On AI Sectors: Heat Dissipation Business Poised to Reach RMB 10 Billion, with Explorations in XR and Robotics Opening New FrontiersIf optics and automotive solutions represent the Company’s “core growth engines,” then business lines such as heat dissipation, robotics, and XR optical waveguides constitute the high-potential “reserves” for AAC’s future development. Dan noted that the Company’s revenue in the past was primarily driven by traditional mobile phone acoustics and haptics business. However, following years of strategic transformation and amid broader industry technological shifts, AI has become the fundamental driver underpinning the sustained growth of the Company’s multiple product lines.“For example, the rapid growth of the heat dissipation business is mainly attributable to AI-driven demand. Similarly, our initiatives in robotics and AR glasses are also propelled by AI,” Dan explained. In 2025, the Company’s heat dissipation business recorded revenue of RMB 1.67 billion, grew by 410.9% year-on-year. This performance has further solidified the Company’s position as one of the leading global suppliers in consumer electronics heat dissipation. “As AI technology continues to advance, related application scenarios are expected to extend from smartphones to a wider range of devices, including laptops and tablets, generating strong momentum for the Company’s overall growth.”The acquisition of Yuandi Technology, with more notable strategic significance, has allowed AAC to formally enter the data center liquid cooling, AI server heat dissipation, and high-end thermal solutions sectors, and extend its capabilities from “terminal-side heat dissipation” to “AI infrastructure heat dissipation” creating a synergistic “terminal + infrastructure” development model. Dan stated clearly, “Leveraging the substantial market opportunities across multiple sectors, our heat dissipation business has the potential to reach and even exceed a scale of RMB 10 billion in the coming years, positioning it as a highly promising and important growth engine for the Group.”In the XR optical waveguide field, through the acquisition of Dispelix — a global leader in AR diffractive waveguide technology — AAC has become one of the few industry players with vertically integrated capabilities spanning optical waveguide design and manufacturing. The Company can now offer one-stop full display module solutions, encompassing optical waveguides, optical engines, push-pull lenses, eye-tracking systems, and electrochromic technology. AAC is expected to become the world’s first supplier to achieve mass production of SRG full-color optical waveguides for leading customers in 2026. Dan disclosed, “The per-unit value in the optics business can reach USD 100–200. These initiatives are expected to deliver clear mass production and shipment opportunities within the next two to three years, continuously generating significant value in revenue, profit, and long-term market expansion.”Regarding the robotics field, Dan pointed out that the industry’s market definition, application scenarios, and product forms are still evolving and remain in a diverse exploratory stage. AAC has long maintained deep involvement and has established comprehensive layouts across multiple core areas, including acoustics, motors, optics, structural components, and electromechanics, laying a solid foundation to capture opportunities as the sector matures. “For example, our dexterous hand products for humanoid robots have already entered mass production and shipments, generating over RMB 100 million in revenue last year. In addition, we are co-developing the first motor, as a core component for AI hardware devices, with our customers. Overall, the Company has built deep cooperation with leading domestic and international customers, and we believe we will become an important player in this field in the future.”4. Strategic Review: Combining Technology Reuse with Ecosystem Construction to Anchor Long-Term GrowthIn AAC’s three-decade development journey, the core driver behind its sustained growth has consistently been rooted in the dual logic of technology reuse and ecosystem construction.Leveraging its long-established, robust technological foundations in micro-acoustics, precision optics, electromagnetic drives, sensors, and semiconductors, the Company has successfully upgraded and expanded its business, with its focus shifting from mobile phones and consumer electronics to emerging high-growth areas, including AI terminals, robotics, XR, smart vehicles, and data center infrastructure. This approach enables its core technological capabilities to be efficiently migrated and continuously amplified across diverse application scenarios.This development model — “upgrading application scenarios without changing underlying technology” — not only ensures the stability and success rate of business transformation but also allows the Company to rapidly address capability gaps through strategic ecosystem integration, such as the acquisitions of Dongyang, PSS, Chuguang, and Yuandi. Together, these efforts have created a virtuous cycle of “technology–product–scenario–customer.”The clear pathway to realizing this cycle was articulated by Dan in her outlook: Looking ahead to 2026 and beyond, AAC will position itself as a “builder of AI perception infrastructure,” deepen cross-business synergy and full-scenario coverage, accelerate its expansion into the “AI blue ocean,” strengthen its global footprint, and continue riding the wave of industry development to achieve new heights.source as Forbes（https://www.forbeschina.com/investment/71292） Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

อ่านเพิ่มเติม

 Financial HighlightsFor the Year Ended 31 December 2025(HK$ million)20252024ChangeRevenue 4,001.13,811.9+ 5.0%Gross Profit 1,385.11,312.1+ 5.6%Gross Profit margin34.6%34.4%+ 0.2ppProfit attributable to owners of the Company 331.4201.0+ 64.9%Net profit margin 8.3%5.3%+ 3.0ppAdjusted EBITDA  622.8612.5+ 1.7%Earnings per share (HK cents) 31.7619.26+ 64.9%HONG KONG, Mar 26 , 2026 - (ACN Newswire via SeaPRwire.com) – Nissin Foods Company Limited (“Nissin Foods” or the “Company”, together with its subsidiaries, the “Group”; Stock code: 1475) today announced its annual results for the year ended 31 December 2025.The Group’s revenue increased by 5.0% year-on-year from HK$3,811.9 million in 2024 to HK$4,001.1 million in 2025, driven by the continued growth of the core instant noodles business, improved consumer sentiment in the Chinese Mainland, and increased demand in overseas markets. Gross profit increased by 5.6% from HK$1,312.1 million in 2024 to HK$1,385.1 million in 2025. Gross profit margin slightly increased by 0.2 percentage points from 34.4% in 2024 to 34.6% in 2025 due to a more favourable sales mix and the Group’s continued implementation of cost efficiency initiatives, which effectively absorbed cost pressure and supported margin improvement.Profit attributable to owners of the Company increased significantly by 64.9% year-on-year to HK$331.4 million, representing a net profit margin of 8.3% for the year. Profit and profitability improved substantially over the year, owing to enhanced operational efficiency and the absence of non-cash charges related to asset impairment losses recognised for the year ended 31 December 2024. The Group’s basic earnings per share increased to 31.76 HK cents for the year. At the Adjusted EBITDA level, the Group recorded an increase of 1.7% from HK$612.5 million in 2024 to HK$622.8 million in 2025, representing an Adjusted EBITDA margin of 15.6% for the year (2024: 16.1%). The Board recommends the payment of a final dividend of 15.88 HK cents per share, representing a dividend payout ratio of 50.0%.Review & Prospects by Business RegionDuring the year under review, revenue from the Hong Kong and other regions operations increased by 7.7% to HK$1,658.7 million, mainly attributable to the steady performance of the instant noodles business in Hong Kong and increased demand in other regions. Segment results rose by 16.1% to HK$152.8 million, driven by continued sales expansion in the premium instant noodles category. Meanwhile, revenue from the Chinese Mainland operations increased moderately by 3.1% to HK$2,342.4 million for the year, with segment results rose by 3.5% to HK$339.9 million, mainly attributable to ongoing efforts to expand sales in inland areas and the sustained sales momentum in the Chinese Mainland.In Hong Kong, the Company continued to enrich its instant noodle portfolio with new SKUs, including Cup Noodles Regular Cup Kyoto Tori Paitan Flavour Instant Noodle and Donbei Meat Broth Flavour Cup Udon (Instant Noodle). To boost sales and consumer engagement, Cup Noodles and Demae Iccho partnered with the virtual singer “Hatsune Miku”. The Company also enhanced its digital marketing in catering channels through a WeChat mini programme. In line with its premiumisation strategy for its frozen food business, the Company launched the Nissin The Chef’s Signature series to cater to consumers seeking elevated home culinary experiences. Meanwhile, the Company continued to broaden its non-noodle portfolio, strengthening its beverage line with seasonal products and expanding the Crisp Choco snack line with a new bite-sized mini version. Hong Kong-made Nissin Granola and fresh-cut vegetable continued to appeal to health-conscious consumers, reinforcing the Company’s commitment to health, wellness and nutrition.For its overseas markets, the Group pursued strategic market expansion and brand enhancement, achieving significant progress. In Vietnam, which remained one of Southeast Asia’s fastest-growing economies, the Company capitalised on strong consumer demand by expanding its sales and distribution channels into modern retail and targeting the youth segment with new products. In Taiwan, the establishment of a wholly-owned subsidiary has provided clearer sales direction and enhanced support to local partners, contributing to sales momentum and long-term business growth. In Korea, the business achieved a solid performance, leveraging the global popularity of K-content and Nissin's international sales network to expand its Gaemi Food Co. Ltd. (“Gaemi Food”) confectionery products into new overseas markets. Meanwhile, in Australia, the Company deepened the operational integration of ABC Pastry Holdings Pty Ltd (“ABC Pastry”) while also broadening its sales network for instant noodle products by capitalising on the growing interest in Asian cuisines across both mainstream and Asian retail channels.In the Chinese Mainland, the Company delivered a solid performance, driven by the volume expansion of its instant noodle business and strategic efforts to expand its geographical footprint into inland regions. To enhance consumer engagement and brand awareness, promotional activities were intensified through increased in-store food tasting, digital marketing on platforms such as the WeChat mini program, and a high-profile collaboration with the Japanese virtual singer “Hatsune Miku”. As part of its premiumisation strategy, the Company enriched its product offerings with new launches such as the Nissin Donbei Kitsune Cup Udon (Instant Noodle). The non-noodle business also demonstrated positive development; the distribution business broadened its portfolio with new premium imported products, including European bottled water, Japanese carbonated beverages, and Japanese chocolate and cookies, while the snack business performed well thanks to its potato chips and festive offerings such as the limited-edition Crisp Choco.Demonstrating a strong commitment to mid- to long-term growth, the Group acquired land use rights of two land parcels in Zhuhai at an aggregate consideration of RMB30.68 million during the year. The Group intends to invest over RMB240 million in acquiring the Land Parcels, constructing new buildings, and installing new production lines.Mr Kiyotaka ANDO, Executive Director, Chairman and Chief Executive Officer of Nissin Foods, said, “We are cautiously optimistic about our growth prospects as we continue to focus on cost control and operational efficiency. The global economy faces an uneven recovery due to geopolitical tensions and supply chain restructuring due to rising trade protectionism. Against this backdrop, we remain committed to continuous product upgrades and execution capabilities in markets where we see clear and sustainable demand. In Hong Kong, government initiatives are expected to underpin the economy and household spending, providing a more favourable environment for the continued premiumisation of our product portfolio. The Chinese Mainland offers significant opportunities with its growing middle class, while Vietnam's thriving retail sector and Korea's focus on health support our strategies. Additionally, the rising demand for high-quality frozen foods in Australia presents valuable growth potential.By leveraging our premiumisation and diversification strategies, we strengthen our competitiveness across these regions. With a solid financial position, cash generation, and strong brand recognition, we are well-positioned for sustained revenue and earnings growth over the medium to long term.”About Nissin Foods Company LimitedNissin Foods Company Limited ("Nissin Foods”, together with its subsidiaries, the “Group”; Stock code: 1475) is a renowned food company in Hong Kong and Mainland China, with a diversified portfolio of well-known and highly popular brands, primarily focusing on the premium instant noodle segment. The Group officially established its presence in Hong Kong in 1984 and is the largest instant noodle company in Hong Kong. The Group primarily manufactures and sells instant noodles, high-quality frozen food products, including frozen dim sum and frozen noodles, and also sells and distributes other food and beverage products, including retort pouches, snacks, mineral water, sauce and vegetable products under its two core corporate brands, namely “NISSIN” and “DOLL” together with a diversified portfolio of iconic household premium brands. The Group’s five flagship product brands, namely “Cup Noodles”, “Demae Iccho ”, “Doll Instant Noodle”, “Doll Dim Sum” and “Fuku” are also among the most popular choices in their respective food product categories in Hong Kong. In the Mainland China market, the Group has introduced technology innovation through the “ECO Cup” concept and primarily focuses its sales efforts in first-and second-tier cities. In addition, Nissin Foods operates business in other regions including Vietnam, Taiwan, Korea and Australia markets.Nissin Foods is currently a constituent of five Hang Seng Indexes, namely: Hang Seng Composite Index, Hang Seng Composite SmallCap Index, Hang Seng Composite Industry Index - Consumer Staples, Hang Seng SCHK Consumption Index and Hang Seng SCHK Consumer Staples Index. Nissin Foods is eligible for trading under Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect. For more information, please visit www.nissingroup.com.hk. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

อ่านเพิ่มเติม

HONG KONG, Mar 26 , 2026 - (ACN Newswire via SeaPRwire.com) – On March 25, CALB (03931.HK) rolled off the production line of the advanced R46 cylindrical battery system at its Chengdu factory, set to power the XPENG ARIDGE X3-F (Land Aircraft Carrier) flying car. According to sources, this power battery product utilizes CALB’s first-unveiled R46 cylindrical battery system technology. Boasting an energy density of 360Wh/kg, the battery stands as the highest-density solid-liquid hybrid cylindrical battery in the industry. It achieves an exceptional balance between high safety, high power density, and high energy density, and will be equipped in several of ARIDGE’s flying car models.The partnership between the two parties began in 2022, with CALB assisting ARIDGE in completing the world’s maiden flight of an electric vertical take-off and landing (eVTOL) flying car. Following a series of rigorous validations, the reliability of CALB’s battery products has been fully verified. Building on this momentum, CALB assembled a team of top researchers to focus on the next-generation advanced R46 cylindrical battery system, tasked with addressing a range of scientific and technological challenges. Furthermore, by taking the lead in collaborating with leading institutions including ARIDGE, the company has been awarded support from the National Key R&D Program Project, further positioning the technologies at the forefront of global innovation in intrinsic safety and high-specific-energy aviation power batteries. Consequently, the two parties have signed a deepened strategic cooperation agreement in April 2025, establishing an exclusive supply relationship for next-generation models.From leading the National Key R&D Program focused on advanced R46 cylindrical battery system technology to achieving mass production of flying car batteries, CALB is accelerating its expansion into forward-looking emerging sectors. The company’s commercialization capabilities across diversified application scenarios continue to strengthen, opening new growth opportunities in the competition for next-generation energy technologies. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

อ่านเพิ่มเติม

TransNusa To Operate Additional Frequencies for Both Singapore-Jakarta and Singapore-Bali Routes- Additional frequencies respond to strong demand for travel between Indonesia and Singapore while strengthening regional connectivity- Both routes received additional scheduled flight slots, providing TransNusa passengers options for day travel- TransNusa increases its minimum baggage allowance to 20kgs, in addition to the 7kg hand carry for it’s minimum package bundle, SEAT, and increased minimum baggage allowance to 30kgs for its highest bundle, Flexi-ProJAKARTA, Mar 25, 2026 - (ACN Newswire via SeaPRwire.com) - PT TransNusa Aviation Mandiri (TransNusa) today announced the launch of additional scheduled flights between Jakarta and Singapore as well as Jakarta and Bali, further strengthening connectivity between two of Southeast Asia’s paramount business and tourism travel hubs.TransNusa Group Chief Executive Officer, Datuk Bernard Francis said that the additional scheduled flight between Soekarno–Hatta International Airport in Jakarta and Singapore Changi Airport will start on April 17 while the additional flight from Gusti Ngurah Rai International Airport in Bali to Changi Airport will start on May 2. Sale of tickets for both additional scheduled flights started on March 17 and can be bought directly from transnusa.co.id or on any main online travel agency platform.The additional flights are part of the TransNusa’s broader strategy to expand regional connectivity and respond to the growing demand for travel between Indonesia and Singapore—two markets with strong economic, cultural, and tourism ties.“Singapore is one of the region’s vital aviation and commercial hub, and these additional flights will provide travellers with greater flexibility while supporting trade and tourism between the two countries,” Datuk Bernard added.“The Jakarta–Singapore corridor is one of the busiest international routes in the region, serving millions of travellers each year. By increasing capacity on this route, we aim to provide a more seamless connections for passengers traveling across Southeast Asia and beyond,” Datuk Bernard stressed, adding that TransNusa’s passengers will benefit from improved scheduling options, allowing for easier same-day connections to a wider network of destinations.“Our goal is to continue improving accessibility across Southeast Asia by increasing frequencies on high-demand routes,” explained Datuk Bernard.Flight DetailsTransNusa’s additional scheduled flight, 8B 155, will depart Jakarta at 07.45pm from Soekarno-Hatta International Airport in Jakarta and arrive at the Singapore Changi Airport at 10.25pm. The flight, 8B 156, will depart Singapore Changi Airport at 11.20pm and arrive at Soekarno-Hatta International Airport in Jakarta at 12.10am.With the launch of this news additional Frequency, TransNusa will be operating three daily flights from Jakarta to Singapore effective April 17, 2026.On the Bali-Singapore route, TransNusa's new scheduled flight, 8B 553, will depart the Gusti Ngurah Rai International Airport at 10.20am and arrive at Changi Airport at 01.15pm. Meanwhile, TransNusa’s flight, 8B 554, will depart Changi Airport at 02.15pm and arrive back at the Gusti Ngurah Rai International Airport in Bali at 05.55pm.TransNusa will be utilising its Airbus A320 for both the international routes.TransNusa, which aims to ensure its passengers travel with ease and comfort, has configured its A320 aircrafts with a 174-seat configuration, which allows for passengers to enjoy about 30 inches of legroom, comparable to the experience passengers would get in a full-service airline."We are committed to providing affordable and competitive ticket prices, while still providing premium services to our customers,” stressed Datuk Bernard.For its international flights, TransNusa not only provides premium services with competitive ticket prices, but the airline also has attractive product bundles called SEAT, SEAT-PLUS and FLEXI-PRO."Our SEAT passengers will now enjoy check-in baggage of 20kgs,” Datuk Bernard said, explaining that the baggage offering was over and above the 7kgs limit offered as a passenger’s hand carry.“For the highest package, FLEXI-PRO, we have increased our baggage allowance to 30kgs, free to choose seats, free food, and drinks, and priority boarding. In addition, TransNusa also provides its FLEXI-PRO passengers with the flexibility to change their flight schedule without restrictions and obtain refund when needed,” concluded Datuk Bernard.About TransNusaTransNusa Airline, is a Premium Service Carrier. In February 2024, the airline rebranded itself to a Premium Service Carrier in line with its upgraded aircrafts that offers better comfort as well as based on the flexibility and quality of the services offered. TransNusa, which received its AOC certification on 9th September 2022, launch its first three A320 operations on 6th October, 14th October and 12th December, 2022.In 2023, TransNusa introduced a new business model making it the first Premium Service Carrier in the Asia Pacific region. TransNusa introduced its first international flight on 14th April, 2023. The airline is currently based in Jakarta and Bali.On the international front, TransNusa flies to Singapore, Guangzhou, Kuala Lumpur, Perth, Shanghai, and Shenzhen. The airline became the second Indonesian airline to fly to China and the first Indonesian airline to launch a Premium Service Carrier business model. Passengers can book their flights on the TransNusa website at www.transnusa.co.id, through any secure online travel agent, through authorized travel agents in Singapore and Indonesia.Primary International Media ContactTrina Thomas RajMobile: +6012 4992672E-mail: trina@myqaseh.org Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

อ่านเพิ่มเติม

CLEVELAND, Ohio, Mar 26, 2026 - (ACN Newswire via SeaPRwire.com) - Formerra, a leader in performance materials distribution, announced the implementation of a transportation surcharge to address continued cost escalation across the Americas freight and logistics market. Beginning April 1, 2026, a $350 per delivery surcharge will apply to all shipments.The freight and logistics market continues to experience elevated costs driven by rising diesel prices, evolving regulatory requirements affecting driver availability, tighter trucking capacity, and increasing operating expenses across the logistics sector. Industry forecasts indicate these pressures will persist for the foreseeable future."Maintaining reliable service for our customers requires us to adapt to sustained shifts in the transportation landscape," said Tom Kelly, Formerra CEO. "This surcharge is necessary to address these industrywide cost pressures that are outside of our control while continuing to provide the high service levels customers expect from Formerra."Customers should contact their Formerra representative for more information.About FormerraFormerra is a preeminent distributor of engineered materials, connecting the world's leading polymer producers with thousands of OEMs and brand owners across healthcare, consumer, industrial, and mobility markets. Powered by technical and commercial expertise, it brings a distinctive combination of portfolio depth, supply chain strength, industry knowledge, service, leading e-commerce capabilities, and ingenuity. The experienced Formerra team helps customers across multiple industries to design, select, process, and develop products in new and better ways - driving improved performance, productivity, reliability, and sustainability. To learn more, visit www.formerra.com.Media ContactJackie MorrisFormerraMarketing Communications Managerjackie.morris@formerra.com+1 630-972-3144SOURCE: Formerra Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

อ่านเพิ่มเติม

Toronto, ON, Mar 25, 2026 - (ACN Newswire via SeaPRwire.com) - Aleen Inc. (CSE: ALEN-U), a digital wellness company, has introduced a new data layer within its Personal Wellness Account, designed to enhance how its AI assistant interprets and structures wellness data.As part of its ongoing product development, Aleen Inc. has implemented a biomarker extraction approach that enables the system to process user-provided data and identify key indicators in a more structured way. This includes the use of a dedicated AI agent that processes documents page by page and extracts relevant biomarkers from wellness data sources.In addition to extraction, Aleen Inc. is developing a standardized structure for each biomarker, including its name, value, unit of measurement, and reference range. These structured data elements are now reflected within the Personal Wellness Account interface. Users will be able to view the total number of detected biomarkers and potential deviations directly within the file list, while a dedicated “Biomarkers” tab in the detailed view provides expanded access to the data in both table and panel formats, along with search and filtering capabilities.This development represents a step toward more structured data environments within Aleen’s ecosystem, supporting improved organization, accessibility, and interaction with wellness data. The introduction of this layer may also contribute to future enhancements in how the system identifies patterns and supports user-centered insights. This update reflects Aleen Inc.’s continued focus on building scalable data architecture and advancing its Personal Wellness Account as a structured, AI-assisted environment for working with wellness data.About Aleen Inc.Aleen Inc. operates as a digital wellness and well-being insights company. Its platform transforms personal wellness information into simple, personalized insights that promote greater self-awareness and balance in daily life. Aleen’s mission is to empower individuals with knowledge and clarity through responsible use of technology and data.For more information, visit www.aleen.ca.Forward-Looking StatementThis press release contains forward-looking statements regarding future plans and developments by Aleen Inc. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Aleen Inc. undertakes no obligation to update or revise these statements except as required by law. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

อ่านเพิ่มเติม

HONG KONG, Mar 25, 2026 - (ACN Newswire via SeaPRwire.com) - On March 25, 2026, Hengrui Pharma (600276.SH; 01276.HK) announced robust financial results for the full year 2025, fueled by its dual strategy of innovation and globalization. Revenue increased 13.02% year-on-year to RMB 31.63 billion, and net profit attributable to shareholders increased by 21.69% to RMB 7.71 billion.Innovation remained the engine of Hengrui’s growth: Innovative drug sales increased by 26.09% year-on-year to RMB 16.34 billion, contributing 58.34% to total drug sales. This was driven by a robust pipeline across therapeutic areas, with oncology products contributing RMB 13.24 billion in revenue (+18.52% YoY), and non-oncology products contributing RMB 3.10 billion in revenue (+73.36% YoY).Hengrui kept innovation at its core, with R&D expenditure reaching RMB 8.72 billion in 2025, accounting for 27.58% of total revenue, of which RMB 6.96 billion was expensed. During the year, the company secured seven approvals for Class 1 innovative drug, one for a Class 2 innovative drug, and six for new indications of marketed innovative drugs. The pace of regulatory progress accelerated with 15 NDA/BLAs accepted by the NMPA. Meanwhile, 28 drug candidates entered Phase III clinical trials, 61 progressed to Phase II, and 28 NMEs entered Phase I for the first time.The company currently has over 100 proprietary innovative products in clinical development and is conducting more than 400 clinical trials. This robust portfolio will be further supported by approximately 53 innovative product and indication approvals anticipated during 2026-2028.2025 marked another year of accelerated progress in Hengrui's global expansion. Licensing revenue rose 25.62% to RMB 3.39 billion, cementing the growing global recognition and value of the company’s innovative portfolio. During the year, the company completed five overseas business development transactions for innovative drugs with leading MNCs and biotechs, highlighted by a strategic collaboration with GSK. In parallel, the company continued to advance its self-developed assets and global regulatory efforts. Multiple innovative drugs had their first global clinical trials initiated, ranging from Phase I to III.Additionally, Hengrui successfully listed on the Hong Kong Stock Exchange, raising total gross proceeds of HK$11.4 billion (US$1.5 billion), including the over-allotment option — marking the largest pharmaceutical IPO in Hong Kong in the past five years and further strengthening its access to global capital.Looking ahead, Hengrui will continue to focus on addressing unmet clinical needs with its differentiated innovative portfolio, placing equal emphasis on independent R&D and open collaboration to expand access to innovative drugs for patients worldwide.About Hengrui PharmaHengrui Pharma is an innovative, global pharmaceutical company dedicated to the research, development and commercialization of high-quality medicines to address unmet clinical needs. Its therapeutic areas of focus include oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. Driven by a patient-focused philosophy since its founding in 1970, Hengrui Pharma remains committed to advancing human health by striving to conquer diseases, improve health, and extend lives through the power of science and technology.Forward-Looking StatementsThis press release contains forward-looking statements, including statements about the company's future growth prospects and pipeline potential. These statements are based on current expectations and assumptions and do not guarantee future performance. Actual results, developments, and business decisions may differ materially from these forward-looking statements. All information in this press release is as of the date of this press release, and Hengrui undertakes no duty to update such information unless required by law. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

อ่านเพิ่มเติม

HONG KONG, Mar 25, 2026 - (ACN Newswire via SeaPRwire.com) - Everbright Grand China Assets Limited, a property leasing, property management and sales of properties held for sale company under China Everbright Group ("Everbright Grand China Assets" or the "Group", Hong Kong Stock Exchange stock code: 3699) today announced the annual results for the year ended 31 December 2025 (the "Year under Review").During the Year under Review, the Group's revenue was approximately RMB49.9 million (2024: approximately RMB45.9 million), representing a increase of approximately 8.7% as compared to last year, mainly attributable to the increase in total rental income from investment properties. The profit attributable to equity shareholders of the Company amounted to approximately RMB19.5 million (2024: approximately RMB25.3 million), representing an decrease of approximately 22.9% as compared to last year. The decrease in profit was primarily due to the increase in dividend withholding tax and deferred tax expenses recognised in 2025. The Board has proposed to pay a final dividend of RMB1.04 cents per share for the year ended 31 December 2025 (2024: RMB1.05 cents). Together with the interim dividend of RMB0.73 cents per share, the full year dividend amounts to RMB1.77 cents per share (2024: RMB2.17 cents per share).As at 31 December 2025, the Group had current assets of approximately RMB241.0 million (2024: approximately RMB239.9 million). The increase in current assets was mainly a result of [the increase in deposits with maturity of more than three months and cash and bank balances during the year].. The Group had current liabilities of RMB20.1 million (2024: approximately RMB19.9 million). The increase in current liabilities was mainly due to he rise in lease liabilities arising from lease renewals.Property LeasingDuring the year under Review, the rental income from the Group’s property leasing business was approximately RMB34.0 million for the year ended 31 December 2025 (2024: RMB30.5 million). Due to increase in the average rent per square metre, and together with rental subsidies offered to tenants, the total rental income increase. As at 31 December 2025, the Group’s property portfolio comprises three commercial buildings, namely Everbright Financial Center, part of Everbright International Mansion and Ming Chang Building, with a total gross floor area (“GFA”) of approximately 89,507 square meters.Property Management ServiceThe Group provides property management services for its properties, namely Everbright Financial Center and Everbright International Mansion. Revenue from the Group’s property management services was approximately RMB15.9 million for the year ended 31 December 2025 (2024: RMB15.4 million). The increase in revenue from property management services was due to the increase in restaurant income. As at 31 December 2025, the total GFA under the Group’s management was 72,534 sq.m.Investment PropertiesThe Group's investment properties primarily consist of land and/or buildings which are owned or held under a leasehold interest to earn rental income and/or for capital appreciation. As at 31 December 2025, the fair value of the investment properties was RMB979.0 million (2024: RMB967.1 million), representing an increase of approximately 1.23%. For the year ended 31 December 2025, the valuation gain on investment properties amounted to approximately RMB10.3 million (2024: approximately RMB6.6 million).PROSPECTSAs the World Bank noted that despite persistent trade tensions, the global economy has demonstrated stronger-than-expected resilience. Amid a complex environment of mounting external pressures and internal challenges, China continued to advance high-quality development, with the overall economy maintaining stable performance and achieving steady progress. With stable economic growth, corporate demand for commercial space has increased. Coupled with accelerated urbanization and the development of new business districts, demand for commercial properties has continued to rise, supporting the growth of commercial property management and leasing activities. In addition, the Chinese government has introduced a series of favourable policies for the commercial real estate sector, focusing on inventory digestion and optimization of industry planning, thereby providing further support to the property management and leasing industry.The Group’s managed properties mainly comprise commercial assets. Despite macroeconomic conditions and market competition, tenancy arrangements, lease agreements and occupancy rates remained stable in 2025. However, rental levels for newly signed leases were lower than in previous periods. To mitigate the pressure arising from rental adjustments, the Group will continue to enhance customer satisfaction by incorporating value-added services into new lease agreements, including property maintenance and upkeep, facilities management and community event planning.The Group’s existing properties are primarily located in Chengdu, Sichuan and Kunming, Yunnan—two key regional cities—and comprise three commercial buildings: Everbright Financial Center, Everbright International Mansion and Ming Chang Building. Benefiting from their prime locations and high-quality facilities, these properties have attracted a sizable number of state-owned enterprises and large institutions, providing a solid foundation for the Group’s leasing business. In recent years, the Group has successfully introduced tenants from emerging sectors such as software and technology, while also offering digitalised services to tenants. Looking ahead, the Group will continue to promote diversified business development and strive to attract more high-quality commercial tenants.In addition, the further escalation of the situation in the Middle East in March 2026 has led to rising energy prices, heightened inflation expectations and slower economic growth, all of which are core factors affecting overseas investment decisions. Accordingly, the Group will carefully reassess its asset allocation and regional risks with respect to its overseas investment plans. Despite the current significant volatility in the global economy, the Group will adhere to the principle of prudent operation, flexibly seize investment windows, and ensure the safety of capital operations.The Group continues to leverage technology to advance smart property management, enhance operational efficiency and elevate the customer experience. By strengthening digitalisation and refined management capabilities, the Group aims to further improve service quality and customer satisfaction.By fully leveraging the synergy with its parent company, China Everbright Group, while actively developing diversified value-added services to broaden its revenue mix and enhance brand influence. As the industry undergoes transformation and upgrading, the Group remains committed to prudent operations, a strong focus on risk management and internal controls, agile responses to macroeconomic and policy developments, continuous optimisation of its asset portfolio, further strengthening of its resilience against market uncertainties, and also actively explore new development opportunities to create greater value for the shareholders.About Everbright Grand China Assets LimitedEverbright Grand China Assets Limited is engaged in the businesses of property leasing and the provision of property management services under China Everbright Group. It owns, leases and manages properties located in Chengdu, Sichuan province, and also owns and leases a property located in Kunming, Yunnan province. The Group's properties are located in the city centers of Chengdu and Kunming, the key cities of western China. The Group's property portfolio includes three commercial properties, namely Everbright Financial Center, part of Everbright International Mansion and Ming Chang Building. For more information about Everbright Grand China Assets, please visit the Company’s website: https://ebgca.com.hk/.This press release is issued by Porda Havas International Finance Communications Group on behalf of Everbright Grand China Assets Limited.For inquiries, please contact: Kelly Fung+852 2590 1900kelly.fung@pordahavas.co Qin Luk+852 2590 1903samantha.luk@pordahavas.comEmail: ebgca.hk@pordahavas.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

อ่านเพิ่มเติม

AALBORG, DENMARK AND MELBOURNE, AU, Mar 25, 2026 - (ACN Newswire via SeaPRwire.com) - The North Jutland technology company NanoNord has, in connection with the Royal Couple's state visit to Australia, secured an order for additional measurement equipment valued at between 160k - 240k AUD from the Australian deeptech pioneer ElectraLith. The order underscores the growing international potential for Danish measurement technology in the green transition.NanoNord was part of the business delegation during the state visit and seized the opportunity to strengthen its business with both existing and new customers in Australia. It is not the first time the Danish Royal Family has been close to NanoNord - the company was originally officially inaugurated by a then-young Crown Prince Frederik.Danish Technology Measures Lithium in Real TimeNanoNord's flagship technology, Tveskaeg, is an MR-based measurement instrument that enables precise real-time measurement of lithium and a range of other elements. The technology is wireless, uses neither chemicals nor disposable materials, and requires minimal calibration and maintenance - making it robust, green, and operationally reliable.ElectraLith uses Tveskaeg instruments as a central part of their groundbreaking DLE-R technology for lithium extraction. DLE (Direct Lithium Extraction) is a new and far more sustainable method for extracting lithium - a critical metal in the batteries powering the green transition. The full potential of the collaboration is up to DKK 10 million over the coming years, as ElectraLith rolls out its technology globally.The two companies connected in Melbourne during the Danish Industry reception 'An Evening in the Name of Business, Sport and Danish Dynamite,' and further strengthened ties during a meeting at ElectraLith's headquarters following the conclusion of the official business delegation.A Happy Customer on the Other Side of the Globe"Tveskaeg is an essential part of our DLE-R system and we are delighted with our partnership with Martin and the NanoNord team. Each DLE-R unit will include a Tveskaeg system to measure lithium and the order of additional units highlights its importance to our operations, particularly as we prepare for rapid global deployment to meet burgeoning demand lithium.Our existing two systems perform flawlessly and intuitively - so much so that our team has named them Forky and Hilda (after King Sweyn ‘Forkbeard' Tveskaeg and his wife). This is our second major order, in what we expect to be many."- Charlie McGill, CEO, ElectraLith"There is nothing better than visiting a customer on the other side of the globe and seeing our technology in use with happy customers like Charlie and his team. Our talented employees back at Skjernvej in Aalborg deserve the credit for the technology simply working and the customers being happy. That we can also bring home an order for additional instruments naturally makes me extra pleased."- Martin Mindorf, CCO, NanoNord"It is a great honour to be part of the historic state visit to Australia, and we are honoured by the attention from especially H.M. the Queen on this trip. The Queen quickly understood the potential of the technology in Australia and asked curiously about how Tveskaeg is used in connection with lithium extraction. NanoNord and ElectraLith are a great example of how our countries can work together, and there is great potential out here, particularly for the extraction of metals that are critical for the green transition. Beyond ElectraLith, we also have several exciting customers and prospects that we need to come back for."- Martin Mindorf, CCO, NanoNordAbout ElectraLithElectraLith is an American deeptech pioneer developing DLE-R - a proprietary electrochemical technology for lithium extraction and refining. The technology produces battery-grade lithium hydroxide or carbonate without water, chemicals, or waste, and can be powered by renewable energy.In December 2024, the company closed a materially oversubscribed Series A round of approximately USD 17 million with investors including Rio Tinto, Chevron, Marathon Petroleum, and In-Q-Tel. In 2026, ElectraLith was selected a Top Innovator by the World Economic Forum and has pilot projects planned in Australia, the United Kingdom, and Argentina.About NanoNordNanoNord was founded in 2001 by inventor Ole Nørgaard Jensen, who previously sold the Bluetooth pioneer company Digianswer to Motorola. The company develops and manufactures MR-based measurement equipment under the name Tveskaeg, used for applications including sodium measurement in food, lithium measurement in the mining industry, and nitrogen and phosphorus measurement in agriculture. Customers include global names such as Kraft-Heinz, Orkla, and Imerys. In the other industries, such as the food industry, NanoNord equipment eliminates the need for silver nitrate titration, and in several European countries, Tveskaeg technology is currently being tested for agricultural applications, where it has the potential to optimise the use of slurry, resulting in less groundwater pollution and better utilisation of nutrients.NanoNord is foundation- and family-owned, with the Lauritzen Foundation as a major investor, and continues to be led by founder Ole Nørgaard Jensen as CEO. In Australia, NanoNord is represented during the state visit by Martin Nørgaard Mindorf, CCO, the next generation of the family.Contact information:Martin MindorfCCOmm@nanonord.dk+4596341590Charlie McGillCEOcharles.mcgill@electralith.comSOURCE: NanoNord Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

อ่านเพิ่มเติม

Brisbane, Australia--(ACN Newswire via SeaPRwire.com - March 25, 2026) - Adyton Resources Corporation (TSXV: ADY) ("Adyton" or the "Company") is pleased to announce positive expansionary drill results from its ongoing exploration program at the 100% owned Feni Island Gold-Copper Project, located on the productive Lihir Trend, Papua New Guinea (PNG). This announcement provides all the assay results for expansionary hole FDD017 (preliminary results were first reported on February 18, 2026).Hole FDD017 previously returned 53m @ 1.29g/t Au (gold only) and now, incorporating newly released copper assays, reports as 53m @ 1.60g/t AuEq representing an approximate 25% increase in reported grade. In addition, strong silver (Ag) and molybdenum (Mo) results further support the presence of a highly fertile epithermal-porphyry at Kabang.KEY HIGHLIGHTS OF DRILL HOLE FDD017Final assays for hole FDD017 have delivered another >100g*m intercept, further confirming strong Au-Cu mineralisation in the north-eastern extension targetHole FDD017 yielded:53m @ 1.29g/t Au, 0.26% Cu (1.60g/t AuEq; from 151m)within a broader interval of 164m at 0.63g/t Au, 0.15% Cu (0.82g/t AuEq for 134g*m; from 36m);including a higher-grade interval that returned: 5m @ 3.6g/t Au, 1.48% Cu (5.63g/t AuEq: from 198m)In addition to gold and copper, FDD017 also reports significant silver and molybdenum signalling strong system fertility for a large alkalic epithermal-porphyry system:5m @ 22.3g/t Ag (from 198m) and 6m @ 275ppm Mo (from 295m; peak Mo 579ppm)These final assay results for hole FDD017 confirm the North-Eastern zone at Kabang is strongly mineralised and prospective for gold and copper and continues to expand this zone beyond the current resource model.Ground based IP/MT survey progressing well; looking to deploy within 2Q 2026."FDD017 continues to exceed our expectations, delivering a meaningful uplift in grade with the inclusion of copper and highlighting the strength of the broader mineralized system at Feni. The increase to 1.60g/t AuEq over 53 metres, combined with strong silver and molybdenum values, reinforces our view that Kabang represents a highly fertile and evolving epithermal-porphyry system. Importantly, this hole further confirms the scale and continuity of mineralization in the north-eastern extension, which remains open and continues to grow beyond the current resource footprint." said Tim Crossley, CEO.Adyton is looking forward to receiving additional assays from nearby drillholes within this zone and updating the market accordingly.SIGNIFICANT INTERCEPTSTable 1 shows the Significant Intercepts for gold and copper assay results received to date (new assays this release for FDD017 only). Figures 1, 2, 3 and 4 show plan map and cross/long sections. See previous release for Table 2 - drillhole status (Feb 18, 2026 news release).Table 1: Gold and Copper Significant Intercepts from Adyton's 2021 (ADK) and 2025/2026 (FDD) drilling at the Feni Island Au-Cu Project (gold, copper and gold equivalent). See footnotes to table: 1 2 3 4To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/7416/289847_b8a30a4df4e5ea26_001full.jpgFigure 1: Feni Project (inset: located on the +120MozAu Lihir Island gold trend), showing Kabang MRE (centre) and numerous, highly prospective, additional target opportunities at Feni. Upcoming IP/MT survey outline highlighted.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/7416/289847_b8a30a4df4e5ea26_002full.jpgFigure 2: Plan view of the Kabang Au-Cu deposit with Significant Intercepts on drill traces (noting numerous drillholes pending assays), with re-processed mag and IP anomalies. The dashed red arcuate line outlines the extent of anomalous Mo and is interpreted to denote the porphyry mineralization footprint based on drilling to date. The green arrow is the vector towards epithermal mineralization based on As-Sb pathfinder elements increasing to the SSW. Pending assays and future drilling will increasingly allow the company to hone-in on porphyry-related and epithermal-related Au-Cu mineralization.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/7416/289847_b8a30a4df4e5ea26_003full.jpgFigure 3: Cross section of hole FDD017 with geology and assays. It highlights the consistent Au-Cu mineralization as punctuated by high-grade gold-copper intercepts within an extensive monzonite/intrusive breccia mineralized zone unit from 36m to 220m.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/7416/289847_b8a30a4df4e5ea26_004full.jpgFigure 4: This long section utilizing recently reprocessed mag and IP data shows the now apparent close correlation of the Danmagal porphyry system evidenced at depth by magnetics data (red polygon >0.16MVI) and the close spatial relationship of the Kabang epithermal system (orange 27mRad IP anomaly) and known gold grades. Of note, geochemical zonation appears to be vectoring towards a hydrothermal fluid source to the SW and to depth - exactly where the Danmagal porphyry is located. Furthermore, the Kabang drilling has encountered smaller apophyses of porphyry style intrusives and copper mineralization, and the current geological model suggests that Danmagal is the likely source of these.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/7416/289847_b8a30a4df4e5ea26_005full.jpgFUTURE CATALYSTS & OUTLOOKAdyton is well-funded with C$16.75m in cash and cash equivalents, 100% earmarked for the Feni Au-Cu Project (plus G&A). The company is executing a systematic exploration strategy to grow the MRE and discover new deposits. Upcoming results and milestones include:Pending Assays:NNE: FDD018, FDD020, FDD023, FDD025, FDD029SSW: FDD019, FDD021, FDD024, FDD026, FDD028Ongoing Drilling: focused on expanding the MRE footprint at Kabang, and testing new targets.Advanced Geophysics: An approximately 5km by 5km ground-based IP & MT survey is being scoped to detect additional deposits on Feni Island and detect deeper prospective targets for drilling (see Figure 1).Spectral Mapping: Deployment of pXRF as well as spectral mineral mapping (1Q 2026) to generate a 3D alteration model for precise vectoring toward the core of the mineralized system with potential high Au-Cu grades to target for drilling.FERGUSSON ISLAND PROGRESS UPDATEEVIH, our 50/50 JV partner, continues to make good progress on the restart of the Wapolu Au Mine. Key areas of significant progress include purchasing and shipping of long lead items and processing plant components. The Mineral Resources authority have also set the date for the ML application Wardens Hearing for May 21, 2026. It is expected that, subject to permitting, Wapolu could be in production in Q4 2026. Adyton does not have any capital expenditure requirements for the Wapolu, these are being provided by EVIH as part of the JV earn-in to the Fergusson projects.QUALITY ASSURANCE / QUALITY CONTROLAdyton adheres to industry-recognized standards of Best Practice and Quality Assurance/Quality Control (QA/QC). Drill core samples were submitted in batches to Intertek Laboratory in Lae, which include a field blank, certified reference materials (CRMs) and staged duplicates. Samples were sealed ensuring Chain of Custody. To date, all batches have passed QA/QC, and blanks and CRMs were within acceptable tolerance limits. All drill holes were drilled and sampled predominantly from PQ and HQ diameter drill core, and to a lesser extent, also NQ core. Core recovery is considered to be appropriate.Qualified PersonThe scientific and technical information contained in this press release has been prepared, reviewed, and approved by Dr Chris Bowden, PhD, GCMEE, FAusIMM(CP), FSEG, the Chief Operating Officer and Chief Geologist of Adyton, who is a "Qualified Person" as defined by National Instrument 43‐101 ‐ Standards of Disclosure for Mineral Projects.ABOUT THE FENI GOLD-COPPER PROJECTThe Feni Project is 100% owned by Adyton and is a key asset in Adyton's portfolio, located in a highly prospective region of Papua New Guinea on the Lihir Island chain known for world-class gold-copper deposits, including Lihir (owned and operated by Newmont). The Company has confirmed significant gold-copper mineralization at Feni, with a focus on expanding its existing resource and identifying new high-grade targets.For further information please contact:Tim Crossley, Chief Executive OfficerE‐mail: ir@adytonresources.comPhone: +61 7 3854 2389Phone: +1 778 549 6768Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.ABOUT ADYTON RESOURCES CORPORATIONAdyton Resources Corporation is focused on advancing gold and copper projects in world-class mineral jurisdictions. The Company holds a portfolio of highly prospective assets in Papua New Guinea where it is actively working to expand its existing gold Inferred and Indicated Mineral Resources and build on recent high-grade gold and copper drill results at its 100% owned Feni Island ‎project.Adyton's projects are located on the Pacific Ring of Fire, on accessible island settings that host several globally significant deposits including the Lihir gold mine and ‎Panguna copper-gold mine on Bougainville Island, both in close proximity to Feni, highlighting the district-scale potential of the Company's land package.Feni Island Au-Cu projectThe Feni Island Project currently has a mineral ‎resource prepared in accordance with NI 43-101 dated October 14, 2021, which has outlined an initial inferred ‎mineral resource of 60.4 million tonnes at an average grade of 0.75 g/t Au, for contained gold of 1,460,000 ounces, ‎assuming a cut-off grade of 0.5 g/t Au. See the NI 43-101 technical report entitled "NI 43-101 Technical Report on the Feni Gold-Copper Property, New Ireland ‎Province, Papua New Guinea prepared for Adyton Resources by Mark Berry (MAIG), Simon ‎Tear (MIGI PGeo), Matthew White (MAIG) and Andy Thomas (MAIG), each an independent mining consultant ‎and "qualified person" as defined in NI 43-101, available under Adyton's profile on SEDAR+ at www.sedarplus.ca. Mineral resources are not mineral reserves and have not demonstrated economic viability.Fergusson Island Au projectThe Fergusson Island Project currently has a mineral resource prepared in accordance with NI 43-101, which outlined an indicated mineral resource of 5.0 million tonnes at an average grade of 1.28 g/t Au for contained gold of 206,000 ounces and an inferred mineral resource of 23.2 million tonnes at an average grade of 0.99 g/t Au for contained gold of 733,000 ounces, both inferred and indicated resources used a 0.5g/t Au cut-off grade.See the technical report dated October 14, 2021, entitled "NI 43-101 Technical Report on the Fergusson Gold Property, Milne Bay ‎Province, Papua New Guinea" prepared for Adyton Resources by Mark Berry (MAIG), Simon ‎Tear (MIGI PGeo), Matthew White (MAIG) and Andy Thomas (MAIG), each an independent mining consultant ‎and "qualified person" as defined in NI 43-101, available under the Company's profile on SEDAR+ at www.sedarplus.ca. Mineral resources are not mineral reserves and have not demonstrated economic viability.See the technical report dated January 7, 2026, entitled "NI 43-101 Technical Report on Wapolu Gold Project" prepared for Adyton Resources by Louis Cohalan (MAIG), an independent mining consultant ‎and "qualified person" as defined in NI 43-101, available under the Company's profile on SEDAR+ at www.sedarplus.ca. Mineral resources are not mineral reserves and have not demonstrated economic viability.For more information about Adyton and its projects, visit www.adytonresources.comTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/7416/289847_adytonmap0103052026.jpgForward-looking statementsThis press release includes "forward‐looking statements", including forecasts, estimates, expectations, and objectives for future operations that are subject to several assumptions, risks, and uncertainties, many of which are beyond the control of Adyton. Forward‐ looking statements and information can generally be identified by the use of forward‐looking terminology such as "may", "will", "should", "expect", "intend", "estimate", "anticipate", "believe", "continue", "plans" or similar terminology. Forward looking statements in this news release include plans pertaining to the drill program, the intention to prepare additional technical studies, the timing of the drill program, uses of the recent drone survey data, the timing of updating key findings, the preparation of resource estimates, and the deeper exploration of high-grade gold and copper feeder systems. The forward‐looking information contained herein is provided for the purpose of assisting readers in understanding management's current expectations and plans relating to the future. Readers are cautioned that such information may not be appropriate for other purposes.Forward‐looking information are based on management of the parties' reasonable assumptions, estimates, expectations, analyses, and opinions, which are based on such management's experience and perception of trends, current conditions and expected developments, the receipt of any necessary permits, licenses and regulatory approvals in connection with the future development of the projects in a timely manner; the availability of financing on suitable terms for the development; construction and continued operation of the Fergusson Island Project and the Feni Island Project; the ability to effectively complete the drilling program; and Adyton's ability to comply with all applicable regulations and laws, including environmental, health and safety laws.Investors are cautioned that forward-looking statements are not based on historical facts but instead reflect Adyton's management's expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of managements considered reasonable at the date the statements are made. Although Adyton believes that the expectations reflected in such forward- looking statements are reasonable, such information involves risks and uncertainties, and under reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements expressed or implied by Adyton. Among the key risk factors that could cause actual results to differ materially from those projected in the forward- looking statements are the following: impacts arising from the global disruption, changes in general macroeconomic conditions; reliance on key personnel; reliance on Zenex Drilling; changes in securities markets; changes in the price of gold or certain other commodities; change in national and local government, legislation, taxation, controls, regulations and political or economic developments; risks and hazards associated with the business of mineral exploration, development and mining (including environmental hazards, industrial accidents, unusual or unexpected formations pressures, cave‐ins and flooding); discrepancies between actual and estimated metallurgical recoveries; inability to obtain adequate insurance to cover risks and hazards; the presence of laws and regulations that may impose restrictions on mining; employee relations; relationships with and claims by local communities and indigenous populations; availability of and changes in the costs associated with mining inputs and labour; the speculative nature of mineral exploration and development (including the risks of obtaining necessary licenses, permits and approvals from government authorities); and title to properties. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those projected in the forward‐looking statements. Such forward‐looking information represents management's best judgment based on information currently available. No forward‐looking statement can be guaranteed, and actual future results may vary materially. Readers are cautioned not to place undue reliance on forward looking statements or information. Adyton Resources Corporation undertakes no obligation to update forward‐looking information except as required by applicable law.1 Interval widths are "apparent" widths downhole, subject to true width determination.2  ADK series drilling (2021) reported previously to TSX.V. Au.eq recalculated here.3 Gold equivalent calculated as: Au.eq = ((Au g/t *0.93) + (Cu% *1.71 * 0.90)). Based on: metal prices of US$2,000/oz Au and US$5/lb Cu; and recoveries of 93% Au and 90% Cu. Recovery assumptions are speculative as no metallurgical test work have been completed at Feni but are based on comparable deposits.4 FDD002 & FDD004 ended in mineralisation.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/289847 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

อ่านเพิ่มเติม